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Dissertation Title: Use of Insulin in Type II Diabetes Meliitus:
Options and Evidence
Research Objective: To explore which insulin formulations and which
regime is the most effective at achieving 
normoglycaemia in Type II Diabetes Meliitus in 
patients who are inadequately controlled with 
maximal oral glucose-lowering therapy?
Background to Research:
The United Kingdom Prospective Diabetes Study (UKPDS) highlighted the 
progressive nature of type II diabetes, showing that a substantial proportion of 
patients will eventually go on to require insulin to achieve their glycaemic target. It 
also helped to establish the benefits of tight glycaemic control in terms of reductions 
in rates of complications.
In the UK, about 20-25% of type II diabetics are estimated to require insulin within 10 
years of diagnosis and it is acknowledged that a greater proportion would probably 
benefit. In the US, approximately 30-40% of type II diabetics are currently receiving 
insulin.
MSc (Pharmaceutical Medicine)
In recent years, the number of formulations available for use has increased with the 
introduction of the rapid acting insulin analogues lispro (Humalog) and aspart 
(Novorapid), and the first soluble long-acting analogue, glargine (Lantus). Increased 
choice has increased speculation as to what is the most efficacious regime.
There is currently no consensus as to which formulations or what regime to use. 
Recent guidance from the National Institute of Clinical Excellence (NICE) asserts 
“there is no direct evidence to support the use/choice of any one insulin type or 
regime over another.” There is also uncertainty as to how to most appropriately 
combine insulin therapy with oral glucose-lowering therapy.
The aim of this research is therefore to ascertain what evidence exists supporting the 
use of various formulations/regimes, what are the advantages and disadvantages of 
each preparation, and what is the most appropriate way of combining insulin therapy 
with oral therapy.
Methodology
I shall conduct a literature review looking for randomised controlled trials and meta­
analysis of studies exploring the use of insulin in type II diabetes. All formulations, all 
regimes and all combinations with oral agents shall be included (acknowledging that 
combining glitazones with insulin is not currently licensed in the UK). I shall use 
Medline and EMBASE to identify relevant published papers (restricting myself to 
English language papers). I shall also seek relevant clinical guidelines from 
professional bodies (such as NICE and the American Diabetes Association) to 
ascertain their current recommendations and to review literature that they reference. I
shall also approach the key pharmaceutical companies in this therapeutic area 
including Eli Lilly, Aventis and Novo Nordisk in order to attempt to obtain 
unpublished research in this field.
Anticipated difficulties
Given the recent NICE guidance proclaiming no direct evidence to support the use of 
one insulin type or regime over another, I expect that there will be insufficient 
available information to enable absolute evidence-based conclusions to be drawn. 
Furthermore, I expect that the pharmaceutical companies may not be overly 
forthcoming in providing me with their unpublished studies.
Dissertation supervisors:
Dr Michael Vanderpump
Consultant Physician and Honorary Senior Lecturer in Endocrinology and Diabetes
Royal Free Hospital Trust, London UK
and
Dr Stephen Thornley
Consultant Physician and Visiting Specialist Endocrinologist 
Sutherland Hospital, Sydney Australia
TABLE OF CONTENTS
1. Title page Page 1
2. Approved dissertation abstract Page 2
3. Table of contents Page 5
4. Acknowledgements Page 6
5. Overview of type 2 diabetes Page 7
6. Normoglycaemia as a therapeutic target Page 22
7. Pharmacologic treatment of blood glucose Page 36
8. Overview of insulin therapy Page 54
9. Systematic review research protocol Page 64
10. Eligible studies overview Page 72
11. Quality appraisal of eligible studies Page 74
12. Evidence tables grouped by treatment comparisons
a. Insulin vs oral hypoglycaemic agents Page 92
b. Different insulin regimens Page 96
c. Insulin in combination with metformin Page 101
d. Insulin in combination with sulfonylurea Page 104
e. Insulin in combination with glitazones Page 110
f. Insulin in combination with acarbose Page 112
13. Conclusions and Recommendations Page 113
14. Appendices
a. Appendix 1: Medline search string Page 123
b. Appendix 2: Embase search string Page 125
c. Appendix 3: Medline eligible studies Page 127
d. Appendix 4: Medline excluded studies Page 138
e. Appendix 5: Embase eligible studies Page 160
f. Appendix 6: Embase excluded studies Page 164
g- Appendix 7: Letter requesting unpublished data Page 189
h. Appendix 8: List of pharmaceutical companies Page 190
approached for unpublished data
i. Appendix 9: Final list of eligible studies Page 191
after quality appraisal
- 5 -
ACKNOW LEDGEMENTS
First and foremost, thank you to my beautiful wife, Claire. When I began this process 
we were just over a year into our relationship, living in Leicester some 20,000km 
from home. We’re now married, back home in Sydney with a mortgage and a cat - 
Life is good. I am forever grateful for her love and support, particularly during those 
moments when the light at the end of the tunnel seemed very distant indeed.
Thank you to Beth Davenport from the PGMS. I have been most appreciative of her 
assistance and encouragement throughout my MSc. She is truly a delightful person 
and I am happy to have met her.
Thank you to Dr Michael Vanderpump from the Royal Free who helped guide this 
project through its fledgling stage.
Thank you to Dr George Pohl, my first boss in pharmaceutical medicine. His support 
made this MSc possible. His wisdom reminded me of the importance of the pursuit of 
knowledge throughout our lives.
Thank you to Dr Stephen Thornley for guiding this dissertation to completion and for 
ensuring my last days in clinical medicine were enjoyable ones. During moments of 
reflection about the choices I have made, it is having a role model like Stephen that 
makes the choice to leave medicine a difficult one.
This dissertation has been a much larger undertaking than I ever imagined. And so I 
finish by acknowledging that.
O verview  o f Type I I  D iabetes
Introduction
Type II Diabetes, the most common endocrine disease, is characterised by 
hyperglycaemia, insulin resistance and relative impairment of insulin secretion. In this 
Chapter, I shall provide an overview of Type II Diabetes including genetic aspects, 
pathophysiology, epidemiology and a brief consideration of its morbidity and mortality.
Genetics
There is a strong genetic influence on the development of Type II Diabetes. Among 
monozygotic twins with one affected twin, the concordance rate is 60-90% (Barnett et al 
1981). Klein et al (1996) conducted a population-based study in people with diabetes and 
found that 39% of patients with older-onset Diabetes had at least one parent with the 
disease. Bennett (1990) has reported that the lifetime risk for a first-degree relative of a 
patient with Type II Diabetes is five to ten times higher than that of age and weight 
matched controls. Further evidence for a strong genetic influence comes from the 
observation that the prevalence of type II diabetes varies markedly between different 
ethnic groups living in the same environment (Carter, Pugh, Monterrosa 1996).
Various groups have examined more than 250 candidate genes, with interest focused 
upon genes coding for proteins that might be involved in insulin secretion or action 
(Kahn 1994). A few cases of Type II Diabetes appear to be associated with mutations in 
genes coding for insulin, mitochondrial components, the insulin receptor, glucokinase 
and glycogen synthase -  at best these count for only a fraction of cases. It is estimated 
that mutations in a single gene that result in decreased insulin secretion or action account 
for less than 5 % of cases of Type II diabetes (Horikawa et al 2000). It is highly likely 
that most of Type II Diabetes is polygenic and the complex interplay of involved genes 
currently eludes us.
Pathophysiology
Patients with Type II Diabetes have two physiological defects (Beck-Nielsen, GroopcO
1994):
i) Abnormal insulin secretion
ii) Insulin resistance in target tissues
Three phases are recognised in the usual clinical sequence. Initially, plasma glucose 
remains normal despite demonstrable insulin resistance, because insulin levels are 
elevated. Most authorities believe that insulin resistance is primary and that 
hyperinsulinaemia occurs as a secondary/compensatory response to the resistance (Foster 
1998). In the second phase, insulin resistance worsens so that postprandial 
hyperglycaemia develops despite elevated insulin concentrations. In the third phase, 
declining insulin secretion causes fasting hyperglycaemia and overt diabetes.
The relative importance of impaired insulin secretion versus insulin resistance has been 
examined fairly extensively, but remains somewhat unclear. Weyer et al (1999) 
demonstrated a decline in insulin-stimulated glucose disposal occurring concomitantly 
with a decline in the acute insulin secretory response in Pima Indians who went on to 
develop diabetes. Chen et al (1995) found that impaired insulin secretion preceded insulin 
resistance in a group of non-diabetic Japanese-American men who went on to develop 
diabetes. It is possible that insulin resistance becomes more severe with increasing age 
and weight, thereby unmasking a concurrent defect in insulin secretion in susceptible 
subjects to cause impaired glucose tolerance and eventually overt hyperglycaemia.
The decline in insulin hypersecretion seen in the third phase may reflect an underlying 
genetic defect or simply reflect metabolic toxicity in the beta cell. Hyperglycaemia itself 
may contribute to further progression by a toxic effect on beta cells, possibly by 
decreasing insulin gene expression (Moran et al. 1997),
Most patients with Type II diabetes are obese, and obesity per se causes insulin 
resistance. The prevalence o f diabetes rises markedly with increasing degrees o f obesity 
(see figure 1). However, nonobese relatives o f persons with Type II Diabetes may have 
hyperinsulinaemia and insulin resistance suggesting that obesity is not the sole cause.
Incrtm in percent desirable weight
Fig 1 -  Increasing body weight increases risk of diabetes
Rates o f impaired glucose tolerance and diagnosed and 
undiagnosed type 2 diabetes in the United States adult 
population according to increase in percent desirable 
weight from age 25 years to age at maximum adult weight 
(about 50 years).Data from Harris M., Diabetes Care 
1989; 12:464
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The importance of the combination of genetic and environmental factors in causation of 
Type II Diabetes is well established. Kahn (1994) studied non-diabetic offspring of two 
parents with Type II Diabetes and found that their insulin sensitivity was similar to that 
of normal subjects with no family history of diabetes at near ideal body weight. With 
increasing degrees of obesity, however, the progressive decrease in insulin sensitivity 
was much more pronounced in those with the family history of Type II Diabetes (See 
figure 2)
Fig 2 -  Obesity decreases insulin sensitivity in 
susceptible subjects
Responsiveness to insulin (as assessed from the intravenous 
glucose tolerance test) according to weight in nondiabetic 
subjects with no family history of type 2 diabetes mellitus 
in first-degree relatives and in those with two parents with 
type 2 diabetes. Data from Kahn C. Diabetes 1994; 43:1066
In association with risk conferred by obesity, lack of physical activity has also been 
shown to increase the risk of developing Type II Diabetes (see figure 3).
- 10-
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Fig 3 -  Importance of body weight and exercise on 
development of type 2 diabetes.
Adjusted incidence of type 2 diabetes in 5990 men in relation to 
body mass index and the level of physical activity. Risk of type 2 
diabetes was directly related to BMI, while exercised was 
protective except for men with a BMI below 24 (i.e. healthy 
weight range) Data from Helmrich S., Ragland D., Leung R., 
Paffenbarger R. N Engl J Med 1991; 325:147
The presence of insulin resistance in obesity and Type II Diabetes led to a theory of the 
“thrifty” genotype, in which insulin resistance may improve survival during states of 
calorific deprivation but lead to diabetes in states of excess (or even adequacy). However, 
other observations have suggested that the ‘thrifty genotype’ may be induced by 
malnutrition during foetal life. Rich-Edwards et al (1999) demonstrated an inverse 
relationship between low birth weight and risk of diabetes mellitus in later life. The 
relative risk of diabetes decreased progressively from 1.8 for a birth weight of <2.3kg to
0.8 for birth weight >4.5kg.
Type II Diabetes is often accompanied by other conditions including hypertension and 
abnormal lipid profiles, particularly high serum small-dense low-density-lipoprotein
- 1 1 -
(LDL) levels and low serum high-density-lipoprotein levels. The constellation of these 
conditions has come to be known as the metabolic syndrome or syndrome X (Reaven 
1988 and DeFronzo, Ferrannini 1991). The World Health Organisation (WHO 1999) has 
subsequently generated a definition of the metabolic syndrome that can be used for 
individual diagnosis. This syndrome is associated with marked increase in risk of 
cardiovascular disease and death.
Metabolic syndrome is defined by the World Health Organization as:
At least one of: Plus at least two of:
- Type 2 diabetes
- Impaired glucose 
tolerance
- Insulin resistance
- Hypertension (BP > 140/90 mmHg)
- Obesity (BMI > 30 kg/m2, or waist- 
hip ratio > 0.90 for men, > 0.85 for 
women)
- Hypertriglyceridaemia
(> 1.7 mmol/L) or low serum HDL 
level (< 0.9 mmol/L for men,
< 1.0 mmol/L for women)
Microalbuminuria (albumin 
creatinine ratio > 2.5 mg/mmol for 
men, >3.5 mg/mmol for women)
Epidemiology
It is estimated that worldwide there are now 150 million people with diabetes, and that 
this number will rise to 300million by 2025 (Zimmet, Alberti, Shaw 2001). In Australia it 
has been reported that 7.4% of the population aged 25 or over had diabetes (type 2 in 
90%), and that about 50% were undiagnosed (Dunstan et al 2002). Prevalence increases 
with age, so that more than 20% of the population aged over 60 had Type II Diabetes.
Dunstan et al. found that the prevalence of Type II Diabetes had doubled between 1981 
and 2000, and that the total number of cases had increased threefold.
Precise figures for the prevalence of the metabolic syndrome are not generally available, 
but, in Australia, the AusDiab study showed a 16% prevalence of impaired glucose 
metabolism (impaired glucose tolerance or impaired fasting glucose). This data, which is 
probably representative of most developed countries, suggests that for every person with 
Type II Diabetes, there is probably at least two more with the metabolic syndrome.
Much is written about the contribution of modern unhealthy diets to the obesity epidemic 
in developed countries. Prentice and Jebb (1995) however, have suggested that modern 
inactive lifestyles are at least as important as diet in the aetiology of obesity and possibly 
represent the dominant factor (see figure 4).
1950 1960
Y«*r
1970
Year
1980 1990
Fig 4 - Secular trends in diet (left) and activity (right) in 
relation to obesity in Britain.
Data from Prentice A., Jebb S. Obesity in Britain: gluttony 
or sloth? BMJ 1995; 311: 437-439.
Morbidity and Mortality
Diabetes is associated with a number of microvascular and cardiovascular complications 
that bring with them substantial morbidity and mortality. The causes of complications in 
Type II Diabetes are not completely elucidated, but over the past few decades a 
substantial body of evidence has accumulated linking hyperglycaemia with the 
development of complications. The presence of complications almost triples the cost of 
managing diabetes (Colagiuri et al. 2002). The major aim of diabetes management is to 
prevent complications.
Type II Diabetes is often part of the ‘metabolic syndrome’, which is associated with other 
risk factors from early in the disease process, including abdominal obesity, hypertension, 
dyslipidaemia, a prothrombotic state and insulin resistance. These factors interplay to 
place the patient with Type II Diabetes at particularly high risk.
Macrovascular disease is the major cause of morbidity and mortality in Type II Diabetes 
(Gaede et al. 2003). Longitudinal studies indicate that the risk of atherosclerotic 
cardiovascular disease is two to four times greater in patients with Type II Diabetes than 
in nondiabetic individuals (Krentz, Bailey 2001). Females with Type II Diabetes lose the 
cardiovascular protection normally conferred by their gender (Kannel, McGee 1979).
Microvascular complications also contribute significant morbidity and are often present 
at the time Type II Diabetes is diagnosed, even in people with no symptoms. Prevalence’s 
at diagnosis have been reported to be: retinopathy, about 20%; neuropathy, 9%; and overt 
diabetic nephropathy, up to 10% (Bate, Jerums 2003).
Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD), 
accounting for 40% of new cases in the Western world. Marshall (2003) reports that 20- 
30% of patients with diabetes have evidence of overt diabetic nephropathy defined as 
persistent clinically detectable proteinuria in association with hypertension and reduced 
glomerular filtration rate. The earliest sign of diabetic renal disease is the presence of 
urinary albumin excretion, termed microalbuminuria (urinary albumin excretion rate, 30-
300 mg/24 h or 20-200 jig/min; or albumin-creatinine ratio > 2.5 mg/mmol in men and 
> 3.5 mg/mmol in women). Annual screening of people with diabetes for this 
complication is recommended. Microalbuminuria identifies individuals at high risk of 
progressing to macroalbuminuria (albumin excretion > 300 mg/24 h, equivalent to total 
protein excretion > 0.5 g/24 h), and also at risk of developing ESRD over a period of 10- 
20 years. Microalbuminuria is also an independent risk factor for cardiovascular disease.
Foot ulcers and amputations are a major cause of morbidity in people with diabetes. They 
result from the presence of peripheral neuropathy, altered biomechanics in the feet and 
peripheral vascular disease (PVD). Annual screening of diabetic patients for peripheral 
neuropathy and PVD is warranted to enable early identification and intervention as 
needed. A podiatrist should assess patients with evidence of disease and all patients 
should be educated about daily foot care.
Diabetic retinopathy is the leading cause of blindness in the adult population
(VanNewkirk et al 2001). Fong et al (2003) report that up to one third of patients with 
Type II diabetes have retinopathies at diagnosis, increasing to two thirds within twenty 
years. In the early stages, the characteristic abnormality is increased vascular
permeability. Without treatment, microvascular occlusions may occur, leading to retinal 
ischaemia and, eventually, the growth of new vessels, termed proliferative retinopathy. 
Macular oedema may occur at any stage as a consequence of increased vascular
permeability. Treatment with laser photocoagulation usually prevents further loss, but
generally doesn’t restore vision already lost. Therefore, retinal screening is warranted at 
least once every two years, to enable early identification of treatable disease before vision 
is lost.
Prevention of Complications
The major goal of therapy in Type II Diabetes is the prevention of the complications 
above. One of the keys to prevention is early identification of those at risk, and a regular 
screening program (see figure 5) is warranted in all patients with diabetes.
Complication
When to 
start Frequency How to screen
Macrovascular
disease
Annually □ Ask about symptoms (intermittent claudication, 
angina [may be atypical] and transient ischaemic 
attack/stroke)
□ Examine pedal pulses, auscultate for bruits, and
□ Use a low “threshold” for electrocardiography and 
exercise stress testing
Microvascular
disease
Retinopathy
T y p e  2
Every 1-2 
years
□ Dilated fundus ophthalmoscopy (usually by an 
ophthalmologist or optometrist) or
□ Fun dal photography
Nephropathy d i a b e t e s :
at
diagnosis
Annually □ Random spot urine sample for albumin-creatinine 
ratio* or
□ Albumin excretion rate in 24 h or timed overnight 
urine collection1
Peripheral
neuropathy
Annually □ Assess protective sensation in feet (eg, with 
Semmes-Weinstem 10 g monofilament)
□ Look for evidence of maldistribution of pressure 
(eg, calluses), and
□ Assess vascular supply and skin integrity
Autonomic
neuropathy
Annually □ Ask about symptoms (nausea and vomiting, 
nocturnal diarrhoea, postural hypotension, erectile 
dysfunction)
Fig 5 -  Screening for complications of diabetes
Data from Bate K., Jerums G. (2003). MJA Practice Essentials -  Endocrinology. 3: 
Preventing complications of diabetes. MJA 2003; 179(9):498-503
Explanatory notes to Fig 5
• Reference range for albumin-creatinine ratio, < 2.5 mg/mmol in men, 
< 3.5 mg/mmol in women.
• t Microalbuminuria should be confirmed with at least 2 specimens, preferably by 
measurement of albumin excretion rate. False positive results occur with recent 
exercise, urinary tract infection, fever, marked hypertension, marked 
hyperglycaemia, congestive cardiac failure and haematuria.
I shall address the evidence supporting the aggressive treatment of hyperglycaemia in the 
next chapter. Much of the intervention in diabetics is aimed at risk reduction, with 
therapeutic targets other than glucose control. There is good evidence supporting 
treatment of hypertension (UKPDS 38 1998, Hanson et al 1998 and HOPE 2000) and 
dyslipidaemia (4S 1994, Sacks et al 1996, HPS 2002 and Sever et al. 2003). The HOT 
study (Hanson et al 1998) also provided evidence for the use of low dose aspirin for all 
people with diabetes and another cardiovascular risk factor, such as dyslipidaemia or 
hypertension. Lifestyle measures including dietary modification, regular exercise and 
smoking cessation should also be advocated (Hu et al 2001 and Tuomilehto et al 2001).
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Norm oglycaem ia as a therapeutic target
Hyperglycaemia and risk of vascular complications
An association between the complications of diabetes and elevated blood glucose was 
first postulated in the early part of last century. However it has only been in the last few 
decades that a substantial body of evidence has accumulated directly linking 
hyperglycaemia with the development of complications (Genuth 1995). Klein et al (1994) 
noted a direct correlation between the degree of glycaemic control and the incidence and 
progression of retinopathy in a study of 1516 patients with diabetes (682 patients with 
diabetes onset <30y.o and 834 patients with onset>30y.o). Gilbert et al (1993) 
demonstrated a similar relationship between glycaemic control and renal disease in Type 
II Diabetics. Epidemiological studies suggest that micro vascular disease occurs with a 
fasting blood glucose (FBG) >7.8mmol/L and macrovascular disease occurs when it is 
>6.1mmol/L (Fuller at al 1980 and Harris 1989). Establishing a relationship between 
glycaemia and complications does not necessarily mean that improving glycaemic control 
will improve outcomes. I shall address the evidence confirming that this does occur 
below.
The Case for Tight Glycaemic Control in Type I Diabetes
The sentinel paper in Type I diabetes was the Diabetes Control and Complications trial 
(DCCT 1993) which provided convincing evidence of the benefits of tight control. This 
study involved 1441 patients with Type I Diabetes and randomly assigned them to 
receive either intensive therapy aimed at achieving near normal glucose levels or 
conventional therapy. In those without evidence of retinopathy at baseline, intensive 
therapy reduced the adjusted mean risk for developing retinopathy by 76%. In a 
secondary prevention cohort (with evidence of retinopathy at baseline), progression of 
retinopathy was slowed by 54%. The occurrence of microalbuminaemia was reduced by 
39%, albuminaemia by 54% and clinical neuropathy by 60% in the intensive therapy 
group. The major adverse event associated with intensive treatment was a two-to-three 
fold increase in the occurrence of severe hypoglycaemia. Significantly, there was no 
discernable glucose threshold, with a continuous reduction in complications as glycaemic
levels approached the normal range. Intensive therapy also reduced cardiovascular events 
in the DCCT, but the difference was not statistically significant.
The Case for Tight Glycaemic Control in Type II Diabetes
Until relatively recently, evidence that tight glycaemic control reduced complications in 
Type II Diabetes was lacking. Before the United Kingdom Prospective Diabetes Studies 
(UKPDS 33 and 34 1998), only three randomised controlled trials existed that attempted 
to assess the benefit of tight glycaemic control on the rate of complications (ADA 2001). 
The first RCT (UGDP 1978) failed to show a benefit in new-onset Type II Diabetics. It 
followed 1000 patients assigned different therapies for about 5.5years and found no 
evidence that improved glycaemic control reduced the risk of vascular endpoints. Of 
note, a major concern that arose from this study was the observation that the sulfonylurea 
(tolbutamide) and a biguanide (phenformin) used to control glucose were actually 
associated with increased cardiovascular mortality. This unexpected finding produced 
new hypotheses as to how some of the glucose lowering drugs may increase 
cardiovascular risk (Smits, Thien 1995).
The first RCT evidence supporting tight glycaemic control was a small study in 110 
Japanese patients (Ohkubo et al. 1995). It compared multiple insulin injections (goal of 
HbAlc<7.0%) with conventional insulin treatment. Patients were divided into a primary 
prevention cohort, with no evidence of retinopathy or nephropathy at baseline, and a 
secondary prevention cohort, with evidence of simple retinopathy and urinary albumin 
excretion>30mg/day. The intensively treated group achieved improved glycaemic control 
(HbAlc 7.1% vs 9.4%), which was associated with significant reductions in 
microvascular complications (retinopathy and nephropathy) similar to that observed in 
the DCCT. Results in the primary prevention cohort were that after six years, tighter 
control reduced the rate of development of retinopathy from 32.0% to 7.7 %, and the rate 
of nephropathy from 28% to 7.7%.
The third RCT (Abraira et al. 1997) randomised 153 men to intensive or conventional 
therapy. It achieved a 2.07% difference in HbAlc between the two groups but failed to 
demonstrate a significant difference in cardiovascular events after a follow-up period of 
27 months.
The United Kingdom Prospective Diabetes Study (UKPDS 33 1998)
The UKPDS (UKPDS 33 and UKPDS 34 1998) provided the evidence that had been 
lacking in support of tight glycaemic control. It is the largest and longest study that has 
ever been conducted on Type II Diabetics. Over 4000 patients were recruited in 23 
centres around the UK between 1977 and 1991. Patients were followed for an average of 
ten years to determine:
i) whether intensive therapy to lower blood glucose would result in clinical 
benefits and
ii) whether the use of various sulfonylurea drugs, metformin or insulin have 
specific therapeutic advantages or disadvantages over one another.
Patients who were hypertensive were also randomised to either ‘tight’ or ‘less tight’ 
blood pressure control to ascertain the benefits of blood pressure lowering. I shall not be 
considering the results of this arm here.
UKPDS 33 randomised 3867 newly diagnosed patients with Type II Diabetes with a 
median age of 54, who after 3 months diet treatment had a mean of two fasting plasma 
glucose (FPG) of 6.1-15.0mmol/L. These patients were randomly assigned to intensive 
treatment with a sulfonylurea (chlorpropamide, glibenclamide, or glipizide) or insulin, or 
conventional treatment with diet. The target for the intensive treatment arm was a 
FPG<6.0mmol/L. In the conventional treatment arm, the aim was the best achievable 
FPG with diet alone, unless the patient had symptoms of hyperglycaemia or a 
FPG> 15 .Ommol/L
Over ten years intensive therapy achieved a median HbAlc of 7.0%(6.2-8.2) compared to 
7.9% (6.9-8.8) in the conventional therapy group, corresponding to an 11% reduction (see 
figure 1).
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Fig 1 -  Glycaemic control in Type II Diabetes
Glycaemic control, estimated from the median HbAlc value, in patients 
with type 2 diabetes in the United Kingdom Prospective Diabetes Study 
on conventional versus intensive therapy. The circles represent data for all 
patients while the lines represent data for patients followed for ten years.
Data from UKPDS 33 Lancet 1998;352:837
This was associated with a 12% risk reduction (p=0.029) for ‘any diabetes-related 
endpoint’. Most of this reduction was due to a 25% reduction (p=0.0099) in the overall 
microvascular complication rate. A 16% reduction in the risk of combined fatal and 
nonfatal myocardial infarction and sudden death was observed, but this failed to reach 
statistical significance (p=0.052). There was no difference for any of the three aggregate 
endpoints (any diabetes-related endpoint, diabetes-related death or all-cause mortality) 
between each of the intensive treatment groups. A table comparing the two treatment 
groups’ rates of single and aggregate endpoints is presented below (see figure 2).
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Fig 1 -  Proportion of patients with aggregate and single endpoints by 
intensive and conventional treatment and relative risks.
Data from UKPDS 33 (1998). Intensive blood-glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk 
of complications in patients with type 2 diabetes. UK Prospective Diabetes 
Study (UKPDS) Group. Lancet 1998; 352:837.
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Overall intensive therapy was considered safe and well tolerated. Patients in the intensive 
group had more hypoglycaemic episodes than those in the conventional group on both 
types of analysis (both p<0.0001). The rates of major hypoglycaemic episodes per year 
were 0.7% with conventional treatment, 1.0% with chlorpropamide, 1.4% with 
glibenclamide, and 1.8% with insulin.
Weight gain was significantly higher in the intensive group (mean 2.9 kg) than in the 
conventional group (p<0.001), and patients assigned insulin had a greater gain in weight 
(4.0 kg) than those assigned chlorpropamide (2.6 kg) or glibenclamide (1.7 kg).
The concern about increased risk of cardiovascular death with sulfonylureas raised by 
UGDP (1978) was not substantiated by UKPDS 33 (1998). No difference in the rates of 
myocardial infarction or diabetes-related death was observed between the groups 
assigned sulfonylurea or insulin therapies.
Epidemiological analysis of the data showed a continuous relationship between risks of 
micro vascular complications and glycaemia, such that for every percentage point 
decrease in HbA12c there was a 35% reduction in risk of complications (ADA 2001). It 
has also demonstrated a continuous association between the risk of cardiovascular 
complications and glycaemia, with each percentage point fall in HbAlc equating to a 
25% reduction in diabetes related deaths, a 7% reduction in all-cause mortality, and an 
18% reduction in combined fatal and non-fatal MI.
UKPDS 34 (1998) -  The Use of Metformin
UKPDS also evaluated the use of Metformin in overweight patients with Type II 
Diabetes. Of the 4075 patients recruited to UKPDS, 1704 were overweight (>120% ideal 
body weight). Of these 753 were included in a randomised controlled trial comparing 
conventional dietary treatment with metformin, aiming for a FPG<6mmol/L. A secondary 
analysis was also preformed comparing the patients allocated metformin (n=342) with the 
951 overweight patients allocated to intensive treatment with sulfonylureas or insulin in 
UKPDS 33. A supplementary RCT was also conducted in 527 patients who had raised
FPG on maximum sulfonylurea therapy. This group were randomised to continuing 
sulfonylurea therapy alone or addition of metformin in equal numbers.
Median H bA lc was 7.4% for metformin compared with 8.0% for conventional treatment. 
Treatment with metformin resulted in risk reductions of 32% for any diabetes related 
endpoint (p=0.002), 42% for diabetes related death (p=0.017), and 36% for all-cause 
mortality (p=0.01). Metformin also showed a greater effect than all other intensively 
treated groups for any diabetes-related endpoint (p=0.0034), all-cause mortality (p=0.021 
and stroke (p=0.032) (see figure 3).
0 3 6 9 12 16
Time from random tart ion, years 
Patients at risk
Convention*! 371 321 239 86 20
Metformin 317 317 222 92 21
Intensive 880 763 546 212 36
Fig 3 -  Metformin in overweight patients with Type II Diabetes
Kaplan-Meier plots of any diabetes-related endpoint in 753 overweight 
patients with type II diabetes in the UKPDS who were randomly assigned 
to either metformin or to conventional treatment with diet. Another 951 
overweight patients received intensive therapy with a sulfonylurea or 
insulin. Data from UKPDS 34. Lancet 1998; 352:854
An unexpected finding was that addition of metformin to patients with persistently 
elevated FPG on sulfonylureas was associated with a 96% increase in diabetes-related 
death (p=0.039) and a 60% increase in all-cause death (p<0.041). It is difficult to know 
how to interpret this finding. The lack of placebo control, the significant cross-over rate 
(25% of the group randomised to sulfonylurea were given metformin) and the inability to 
employ masking in this substudy have all raised doubts over the validity of these 
detrimental findings. Epidemiological analysis conducted by the investigators did not 
corroborate an association between combined therapy and diabetes-related deaths but 
confidence intervals were wide.
Another finding of note is that metformin failed to achieve a statistically significant 
reduction in microvascular complications, though the trend was for a risk reduction of 
29% (p=0.19).
Metformin would seem to be the first line treatment of choice in obese patients with Type 
II Diabetes -  indeed, it was the only treatment that achieved a significant reduction in 
cardiovascular outcomes. This may relate to the absence of weight gain with metformin 
use and/or to some beneficial effect of metformin on the metabolic syndrome. Further 
study is warranted to explore any possible detrimental effects when metformin is added 
to therapy with sulfonylureas.
Macrovascular Disease -  an Outstanding Question?
As detailed above, there is adequate evidence that tight glycaemic control significantly 
reduces the risk of occurrence and progression of microvascular complications. There are 
however, conflicting data on the importance of glycaemic control on the development of 
macrovascular disease in type II Diabetes. A prospective study in Finland, which 
followed 1069 nondiabetic and 229 subjects with Type II Diabetes for 3.5 years, found 
that a high HbAlc was a strong predictor of cardiovascular death and of all CHD events, 
particularly in women (Kuusisto et al. 1994). In contrast, the Patient Outcomes Research 
Team (Meigs et al 1997) found the prevalence of cardiovascular disease was constant
across increasing quartiles of HbAlc values. Cardiovascular disease was associated with 
traditional risk factors and with the duration of diabetes.
In UKPDS 34 (1998) Metformin achieved a 39% lower risk (p=0.010) of myocardial 
infarction than conventional treatment. This compared to a non-significant 16% risk 
reduction (p=0.052) for patients treated with insulin or sulfonylureas in UKPDS 33 
(1998).
The VACSDM study (Abraira et al 1997) of 153 men with Type II Diabetes found a non­
significant (p=0.1) i n c r e a s e d  risk of new cardiovascular events in patients receiving 
intensive therapy (multiple injections +/- a sulfonylurea) compared to those on a single 
insulin injection daily. It is worth noting that this was a much smaller trial than UKPDS 
and that the diabetic patients in the VACSDM were not newly diagnosed and had a 
higher prevalence of cardiovascular risk factors.
There is evidence that the relationship between blood glucose levels and cardiovascular 
risk extends into the nondiabetic range (Coutinho et al 1999). Khaw et al (2001) followed 
a cohort of 4662 men aged between 45 and 79 and found all cause mortality and 
cardiovascular deaths were significantly higher among those with an HbAlc in the high 
end of normal compared with those with a HbAlc<5.0% (see figure 4). An increase of 
1% in HbAlc was associated with a 28% (P<0.002) increase in risk of death independent 
of age, blood pressure, serum cholesterol, body mass index, and cigarette smoking habit.
Further evidence of the detrimental cardiovascular effects of poor glycaemic control is 
provided in a relatively short-term study by Iribarren et al (2001). They followed almost 
50000 predominantly Type II Diabetic patients with no heart failure at baseline for a 
mean of 2.2 years and found each 1% increase in HbAlc was associated with an 8% 
increased risk of heart failure. A HbAlc >10% increased the risk of heart failure by 1.6- 
fold compared with a HbAlc<7%.
Fig 4 -  HbAlc as a predictor of mortality
In a study of men aged 45 to 79, H bA lc was correlated with 
cardiovascular and all-cause mortality, even within the nondiabetic range.
Data from Khaw K., W areham N., Luben R., Bingham S., Oakes S.,
Welch A., Day N. Glycated haemoglobin, diabetes, and mortality in men 
in Norfolk cohort of European prospective investigation of cancer and 
nutrition (EPIC-Norfolk). BMJ 2001 Jan 6; 322(7277): 15-8.
There is a large evidence base demonstrating that hyperglycaemia is a strong predictor of 
cardiovascular risk. To date randomised controlled trials have failed to convincing 
demonstrate that tight glycaemic reduces this risk, but it is worth noting that the largest of 
them (UKPDS 1998) did show a statistically non-significant trend in the direction of risk 
reduction. Early concerns about a potential to increased cardiovascular risk with 
sulfonylureas and insulin therapy have not been substantiated by UKPDS.
Conclusions
Tight glycaemic control in Type II Diabetics is associated with a decreased risk o f 
microvascular complications. Outcomes improve for every 1% drop in H bA lc and there 
does not seem to be a threshold effect. Benefits in terms of macrovascular complications
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are yet to be convincingly established, but concerns about a possible detrimental effect 
have now been largely allayed.
We now have a greater understanding of the progressive nature of Type II Diabetes and 
the fact that this necessitates a combination of therapies if glycaemic targets are to be 
attained. The use of multiple therapies creates cost considerations both for patients and 
health care systems alike, but the costs of therapy must be offset against the savings 
obtained through avoidance of complications.
We can feel confident that tight glycaemic control can be attained safely. However, we 
must be mindful of the observed increased risk of hypoglycaemic events in the more 
intensively treated patients. Weight gain associated with certain therapies may also have 
implications for patient acceptability of intensive treatment regimes. Each patient should 
be encouraged to get their HbAlc as close to normal as is practically possible.
The American Diabetes Association (ADA) currently recommends a target of less than
7.0 percent for most patients, while the American Academy of Clinical Endocrinologists 
(AACE) and the European Association for the Study of Diabetes (EASD) both 
recommend a target of HbAlc less than 6.5 percent. Given that the risk of all cause death 
and cardiovascular death is higher among those with HbAlc between 5.0 to 6.0 percent 
than it is for people with HbAlc less than 5 percent (Khaw et al 2001), it is likely that 
recommended targets will continue to fall in the future.
Finally, it would be remiss not to highlight the fact, that glycaemic control is simply one 
aspect of the management of patients with Type II Diabetes. Vigorous cardiac risk 
reduction with advice on smoking cessation, appropriate use of aspirin, tight blood 
pressure control, management of dyslipidaemia, lifestyle modifications including diet and 
exercise, and use of angiotensin converting enzyme inhibitors when appropriate, should 
all be considered as part of the management of patients with Type II Diabetes. It is only 
through a multifaceted approach that we can hope to optimise the care and improve the 
quality of life of patients with Type II Diabetes.
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P h a r m a c o lo g ic  T r e a tm e n t  o f  B lo o d  G lu c o s e
Diet, weight reduction and exercise should all be part of the measures used to improve 
glycaemic control in Type II Diabetes. These measures can be very effective, but 
compliance is not sustained in most patients (Schneider et al 1992 and Uusitupa et al
1993). As a result, pharmacologic treatment is eventually required in most patients.
There are currently four therapeutic drug options for Type II Diabetes:
1 ) Increase insulin release with a sulphonylurea or meglitinide
2) Increase insulin responsiveness with a biguanide (metformin) or a
thiazolidinedione.
3) Modify intestinal absorption of carbohydrate with an alpha-glucosidase 
inhibitor, or absorption of fat with a lipase inhibitor.
4) Administer exogenous insulin.
Sulphonylureas
C l i n i c a l  U s e
Sulfonylureas are the most widely used drugs for the treatment of patients with Type II 
Diabetes (Bressler, Johnson 1997). They may be used as monotherapy, or in combination 
with other oral hypoglycaemic drugs or insulin. Most patients who are normal weight or 
only moderately obese are begun on a sulphonylurea. A 20% lowering of blood glucose 
concentrations should be expected (Groop 1992, Herman et al 1994 and UKPDS 13 
1995).
The sulphonylureas act mainly by augmenting insulin secretion and consequently are 
effective only when some residual pancreatic beta-cell activity is present. Several 
sulphonylureas are available and their efficacies are felt to be fairly similar. Choice is 
therefore determined by cost, availability, side effects and duration of action, as well as 
the patient’s age and renal function. Although the manufacturers recommend doses as 
high as 20-40mg/day for glipizide or glibenclamide, doses above lOmg/day usually have 
little further effect (Stenman et al 1993).
P h a r m a c o k i n e t i c s
Glipizide, glibenclamide and glimepiride are so-called second-generation sulphonylureas. 
They have structural characteristics that enable them to be given at much lower doses 
than the first generation drugs.
The long acting sulphonylureas chlorpropamide, glimepiride and glibenclamide can be 
given once daily. They cause greater suppression of overnight hepatic glucose output, 
thereby lowering fasting blood glucose more. They are however associated with a greater 
risk of hypoglycaemia and are best avoided in elderly patients, where short acting 
alternatives gliclizide or tolbutamide should be used instead (Shorr et al 1996).
S i d e  E f f e c t s
Sulphonylureas are usually well tolerated. Hypoglycaemia is the most common side 
effect and is more common with long-acting sulphonylureas as stated above. Patients 
should be educated about the symptoms of hypoglycaemia and what steps to take if it 
occurs.
Other infrequent side effects include nausea, skin reactions and abnormal liver function 
tests. Chlorpropamide has two unique effects: it can cause an unpleasant flushing reaction 
after alcohol ingestion by inhibiting acetaldehyde metabolism (Groop et al 1984); and it 
can cause hyponatraemia (Kadowaki et al 1983). As a result of these occurrences (and the 
higher risk of hypoglycaemia) chlorpropamide should no longer be recommended.
Meglitinides
The meglitinides, repaglinide and nateglinide, are short acting glucose lowering drugs 
that may be used as monotherapy or in combination with metformin. They are 
structurally different from sulphonylureas but act similarly by regulating ATP-dependent 
potassium channels in pancreatic beta-cells, thereby increasing insulin secretion 
(Fuhlendorff et al 1998).
The clinical efficacy of repaglinide is similar to that of the sulphonylureas 
(Wolffenbuttel, Landgraf 1999). It can also be given in combination with metformin 
(Moses et al 1999). Doses are taken before each meal and should be skipped if a meal is 
missed (Moses et al 2001 and Schmitz et al 2002).
Repaglinide is considerably more expensive than the sulphonylureas and is yet to 
demonstrate any therapeutic advantages over them. This has limited its use in clinical 
practice to date.
The Food and Drug Adinistration have approved Nateglinide, a new drug in this class, for 
monotherapy or in combination with metformin. In the UK it is only indicated in 
combination with metformin. As monotherapy it is less effective than metformin, but 
combination therapy has been shown to be more effective than either drug alone (Horton 
et al 2000). In a comparison study with glibenclamide, both drugs produced similar 
degrees of overall mealtime glucose control; nateglinide had a greater effect on mealtime 
glucose excursions, while glibenclamide had a greater effect on fasting blood glucose 
(Hollander et al 2001).
Biguanides (Metformin)
A c t i o n s
Metformin is the only biguanide that is currently available. It is particularly useful in 
obese patients with Type II Diabetes since it does not increase insulin secretion. It is 
effective only in the presence of insulin, and its major effect is to increase insulin action 
(Bailey, Turner 1996). The mechanism by which metformin increases insulin action is 
not known. Postulated mechanisms include suppression of hepatic glucose output, 
increased insulin-mediated glucose utilisation in peripheral tissues and an antilipolytic 
effect that lowers serum free fatty acid concentrations, thereby reducing substrate for 
gluconeogenesis (Bailey 1992 and Stumvoll et al 1995). Metformin also increase 
intestinal glucose utilization via nonoxidative metabolism. The lactate produced by this 
process is largely metabolised in the liver as a substrate for gluconeogenesis, which may 
protect against hypoglycaemia.
C l i n i c a l  U s e
Metformin is most often used in obese patients, because it promotes modest weight 
reduction or at least weight stabilisation (see figure 1). In the UKPDS 24 (1998), for 
example, among obese patients in the primary diet failure group, those allocated to 
insulin had a greater mean increase in body weight (10.4 kg) than those allocated to a 
sulfonylurea (3.7 kg) or metformin (no significant change).
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Fig 1 -  Weight change with drug therapy in Type II Diabetes
Mean change in body weight over six years in a group o f obese 
patients with type 2 diabetes who were allocated to therapy with 
insulin, sulphonylurea or metformin. Data from United Kingdom 
Prospective Study Group. Ann Intern Med 1998; 128:165
Metformin typically lowers blood glucose concentrations by 20%, a response similar to 
that achieved with a sulphonylurea (Hermann et al 1994). The US Multicentre Metformin 
Study Group also found that patients not well controlled with glibenclamide alone had a 
substantial improvement in fasting blood glucose when metformin was added (DeFronzo,
Goodman 1995). The main indication for combination therapy is an inability to achieve 
glycaemic control with either drug alone, particularly in a patient who does not want to 
take insulin.
In addition to avoidance of weight gain, metformin has two other advantages over the 
sulphonylureas. It is less likely to cause hypoglycaemia and it has prominent lipid 
lowering activity, resulting in a decrease in serum triglyceride and free fatty acid 
concentrations, a small decrease in LDL-cholesterol and an increase in HDL-cholesterol 
(Wu et al 1990). These are however offset against two disadvantages: the risk of lactic 
acidosis and prominent gastrointestinal side effects.
P h a r m a c o k i n e t i c s
Metformin is absorbed rapidly from the small intestine, with peak plasma concentrations 
obtained in two hours. It is not bound to plasma proteins, is not metabolised, and is 
rapidly excreted in the urine with a half-life of 1.5-4.9 hours.
Metformin is available as a 500 and 850mg tablets and should be taken with meals. 
Starting dose is 500mg daily increased slowly as necessary to a maximum of 2550mg 
daily (850mg tds). It is important to start low and increase gradually to decrease the 
likelihood of gastrointestinal complications, which have the potential to impact greatly on 
patient compliance.
S i d e  e f f e c t s
The most common side effects are gastrointestinal, including a metallic taste in the 
mouth, anorexia, nausea, abdominal discomfort and diarrhoea. These symptoms are 
usually mild, transient and reversible after dose reduction or discontinuation.
Metformin also reduces absorption of Vitamin B12 in up to 30%, which may lower 
serum B12 levels and rarely, lead to megaloblastic anaemia -  this can be corrected by 
oral administration of calcium (Bauman et al 2000).
L a c t i c  A c i d o s i s
Metformin may cause lactic acidosis. Stang et al (1999) reported the incidence of lactic 
acidosis in patients taking metformin to be 9 per 100 000 person-years. This compares 
with a rate of 40-64 per 100,000 patient years in patients taking the old biguanide, 
phenformin. However, in a systematic review of 176 studies including 35619 person- 
years of metformin therapy, there were no cases of lactic acidosis.
Certain conditions predispose to serious lactic acid accumulation and are therefore 
relative or absolute contraindications to metformin:
- renal insufficiency
liver disease or alcohol abuse 
heart failure
past history of lactic acidosis
severe infection with decreased tissue perfusion
hypoxia
haemodynamic instability 
serious acute illness 
age > 80 years
Metformin should also be stopped 48hours prior to receiving intravenous iodinated 
contrast material due to potential nephrotoxicity of iodine. In a review of 110 published 
cases of metformin associated lactic acidosis, nine occurred in patients with contrast- 
induced renal failure (Sirtori, Pasik 1994).
Most cases of lactic acidosis associated with metformin have occurred in patients with 
shock or tissue hypoxia (Lalau et al 1995). However it can occur in patients with normal 
renal and hepatic function (Pepper, Schwartz 1997).
Thiazolidinediones
There are currently two thiazolidinediones available on the market: rosiglitazone 
(Avandia) and pioglitazone (Actos). The first drug in this class, troglitazone (Rezulin),
was removed from the market because it caused liver dysfunction and in some cases liver 
failure.
These drugs increase insulin sensitivity by acting on muscle and liver to increase glucose 
utilisation and decrease glucose production (Nolan et al 1994 and Iwamoto et al 1996). 
They also increase insulin secretion in response to glucose, at least in patients with 
impaired glucose tolerance (Cavaghan et al 1997). This finding suggests that the 
thiazolidinediones can improve the early beta-cell dysfunction that occurs in patients with 
impaired glucose tolerance.
C l i n i c a l  U s e - M o n o t h e r a p y
Most of the available efficacy data is for troglitazone, which is no longer available. It is 
felt that the efficacy of all three drugs is similar, but no comparative studies have been 
undertaken (McCulloch 2003).
Aronoff et al (2000) conducted a six-month trial of monotherapy with three dose levels of 
pioglitazone and found significant reductions in HbAlc (range -1.0 to -1.6% compare 
with placebo) and fasting blood glucose (-2.2 to -3.6mmol/L compared with placebo). 
There were also significant decreases in triglycerides, increases in HDL cholesterol, and 
only small changes in total cholesterol and LDL. The overall adverse event profile of 
pioglitazone was similar to that of placebo and no evidence of hepatotoxicity was found.
A six-month trial of rosiglitazone demonstrated similar efficacy (Lebovitz et al 2001). 
Rosiglitazone (2 and 4 mg bd) decreased mean HbAlc relative to placebo by 1.2 and 
1.5% respectively, and reduced fasting plasma glucose concentrations relative to placebo 
by 3.22 and 4.22 mmol/L, respectively.
Rosiglitazone and pioglitazone have similar effects on glycaemic control, but their effects 
on serum lipids may be slightly different. Khan et al (2002) randomised 127 diabetic 
patients previously treated with troglitazone to either pioglitazone or rosiglitazone for 
four months. Glycaemic control and weight gain (2kg) were the same in both groups.
However, serum total and LDL cholesterol decreased with pioglitazone but not with 
rosiglitazone.
C l i n i c a l  U s e  -  C o m b i n a t i o n  t h e r a p y
The thiazolidinediones have been studied in combination with insulin, sulphonylureas 
and metformin (Schwartz et al 1998, Horton et al 1998, Inzucchi et al 1998, Fonseca et al 
2000, Raskin et al 2001).
Fonseca et al (2000) evaluated the use of rosiglitazone in 348 patients who were 
inadequately controlled with metformin alone. Patients were randomised to continued 
metformin alone or metformin in combination with rosiglitazone (4mg/d or 8mg/d). Over 
six months, the mean levels of HbAlc decreased by 1.0% in the 4 mg/d metformin- 
rosiglitazone group and by 1.2% in the 8 mg/d metformin-rosiglitazone group and fasting 
plasma glucose levels by 2.2 mmol/L and 2.9 mmol/L compared with the metformin- 
placebo group (P< 0.001 for all).
Raskin et al (2001) conducted a similar study evaluating rosiglitazone in combination 
with insulin. 319 type 2 diabetic patients with mean baseline HbAlc > 7.5% on twice- 
daily insulin therapy (total daily dose > 30 U) were randomised to 26 weeks of additional 
treatment with rosiglitazone (4 or 8 mg daily) or placebo. Treatment with rosiglitazone 
8mg plus insulin resulted in a mean reduction from baseline in HbAlc of 1.2% (P <
0.0001), despite a 12% mean reduction of insulin dosage. However, post-marketing 
studies of this combination have reported an increased incidence of heart failure, 
suggesting that use of this combination therapy be limited (FDA 2002). Indeed, this 
combination therapy is not a licensed indication in the UK.
Kipnes et al (2001) evaluated the efficacy of combined pioglitazone and sulphonylurea 
therapy in a study of 560 patients with inadequate glycaemic control on sulphonylurea 
therapy. The patients who received pioglitazone (15 or 30mg) plus the sulphonylurea had 
significant decreases in HbAlc (0.9 and 1.3% lower respectively) than those who
received sulphonylurea plus placebo. Pioglitazone was also observed to have favourable 
impact on serum lipids.
W e i g h t  g a i n
All of the thiazolidinediones cause weight gain (see figure 2). It is both dose-dependant 
and time dependent. The weight gain is caused by both proliferation of new adipocytes 
and redistribution of fat stores. Fluid retention may also be a contributing factor.
W eight increased in both a time and dose dependant fshion in patients 
treated with different thiazolidinediones for six months. T200, T400, and 
T600 = troglitazone 200, 400 and 600mg daily; P I5 and P45 = 
pioglitazone 15 and 45mg daily; R4 and R8 = rosiglitazone 4 and 8mg 
daily.Data from Arnoff S., Rosenblatt S., Braithwaite S et al. Diabetes 
Care 2000; 23:1605; Fonseca V., Rosenstock J., Patwardhen R., Salzman 
A. JAMA 2000; 283:1695; Schwartz S., Raskin P., Fonseca V., Graveline 
J. N Eng J Med 1998; 338:861; and Akazawa S., Sun F., Ito M et al. 
Diabetes Care 2000; 23:1067
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H e p a t o t o x i c i t y
As mentioned above, troglitazone was removed from the market because of reports of 
severe hepatocellular injury. Rosiglitazone was not associated with hepatotoxicity in 
clinical trials involving approximately 5000 patients (Lebovitz, Kreider, Free 2002). 
There have however been case reports of hepatic toxicity in at least two patients receiving 
rosiglitazone (Forman, Simmons, Diamond 2000 and Al-Salman et al 2000). Two cases 
of hepatotoxicity have also been reported with pioglitazone (Maeda 2001 and May et al
2002). Monitoring of liver function is thus recommended every two months during the 
first year of therapy and periodically thereafter,
Alpha-Glucosidase Inhibitors (Acarbose)
Acarbose is the only available alpha-glucosidase inhibitor in the UK. It acts by inhibiting 
the upper gastrointestinal enzymes (alpha-glucosidases) that convert carbohydrate into 
monosaccharides in a dose dependent fashion. This effect slows absorption of glucose, 
which leads to a lower postprandial peak in blood glucose. Meneilly et al (2000) also 
found that acarbose increased insulin sensitivity in a group of 45 elderly patients with 
type II Diabetes. It has a small but significant effect in lowering blood glucose and may 
be used as monotherapy or in combination with metformin or sulphonylureas.
E f f i c a c y
Several trials have demonstrated the efficacy of acarbose in patients with Type II 
Diabetes. Hoffman et al (1994) randomised 96 patients inadequately controlled with diet 
to receive glibenclamide, acarbose or placebo. Compared with the placebo, both drugs 
showed the same mean efficacy on fasting blood glucose (-1.4 mmol/L with acarbose, - 
1.6 mmol/L with glibenclamide), lhr postprandial blood glucose (-2.2 mmol/L with 
acarbose, -1.9 mmol/L with glibenclamide), and HbAlc (-1.1% with acarbose, -0.9% 
with glibenclamide).
Another study by Chiasson et al (1994) recruited 354 patients with non-insulin-dependent 
diabetes mellitus; 77 were being treated with diet alone, 83 with diet and metformin, 103
with diet and sulfonylurea, and 91 with diet and insulin. Patients in each treatment group 
were randomly assigned to either acarbose or placebo for 1 year. The addition of 
acarbose in each of these groups reduced the mean post-prandial blood glucose 
concentration by 3.5mmol/L. Corresponding decreases in HbAlc levels occurred; these 
were 0.9% in the diet alone group (P = 0.005), 0.8% in the metformin group (P = 0.011),
0.9% in the sulfonylurea group (P = 0.002), and 0.4% in the insulin group (P = 0.077).
Acarbose may also have beneficial effects on serum lipid concentrations. Hoffman and 
Spengler (1997) studied a group of 96 patients randomised into 3 groups and treated for 
24 weeks with acarbose, 3 x 100 mg/day, or metformin, 2 x 850 mg/day, or placebo. 
Efficacy was similar between metformin and acarbose; HbAlc was 9.8% with placebo, 
8.5% with acarbose, and 8.7% with metformin. The acarbose group had a 27% decrease 
in the ratio of LDL-cholesterol to HDL-cholesterol, due to both a decrease in LDL (4.1 to 
3.2mmol/L) and an increase in HDL (1.4 to 1.6mmol/L). By comparison, the metformin 
group had no change and the placebo group had a 14% increase in the serum LDL/HDL 
ratio.
S i d e  e f f e c t s
Gastrointestinal side effects are very common with use of acarbose and have considerably 
limited its use. The occurrence of flatulence and diarrhoea has been observed to limit 
patient compliance in clinical trials (Holman, Cull, and Turner 1999). Careful titration of 
acarbose is needed in order to minimise these adverse effects.
Lipase Inhibitors (Orlistat)
Orlistat (Xenical) is a minimally absorbed drug that inhibits pancreatic and gastric 
lipases, blocking absorption of approximately 30% of ingested fat. Two studies in obese 
subjects over two years have demonstrated orlistat to achieve significantly more weight 
loss than placebo (see figure 3) (Sjostrom et al 1998 and Davidson et al 1999).
Fig 3 -  Weight loss in obese subjects on orlistat
Mean body weight change during two-years treatment with diet plus 
orlistat or placebo. The patients initially received a reduced energy diet 
and, at one year, a maintenance diet. Orlistat therapy was associated with 
more weight loss and less weight regain. Data from Davidson M., 
Hauptman J., DiGirolamo M et al. JAM A 1999; 281:235.
In diabetic patients, the weight loss induced by orlistat is associated with improved 
glycaemic control. Hollander et al (1998) randomised 391 obese subjects with type II 
diabetes on sulphonylureas to receive either orlistat 120mg tds or placebo. After 1 year of 
treatment, the orlistat group lost 6.2kg of initial body weight vs. 4.3kg in the placebo 
group (P < 0.001). Orlistat treatment plus diet compared with placebo plus diet was 
associated with significant improvement in glycaemic control, as reflected in decreases in 
H bA lc (P < 0.001) and fasting plasma glucose (P < 0.001) and in dosage reductions of
oral sulfonylurea medication (P < 0.01). Orlistat therapy also resulted in significantly 
greater improvements than placebo in several lipid parameters, namely, greater 
reductions in total cholesterol, (P < 0.001), LDL cholesterol (P < 0.001), triglycerides (P 
< 0.05), apolipoprotein B (P < 0.001), and the LDL-to-HDL cholesterol ratio (P < 0.001).
Similar weight loss and improved lipid profiles have also been observed in trials of 
orlistat in diabetics on metformin (Miles et al 2002) and also in diabetic patients 
receiving insulin (Kelley et al 2002). Orlistat may therefore be a useful adjunctive 
therapy for obese patients with Type II Diabetes.
Insulin
I shall provide an overview of available insulin therapies in the next chapter. Patients 
with Type II Diabetes who have persistent hyperglycaemia despite diet, weight reduction 
and exercise are typically started on an oral hypoglycaemic drug. Insulin is usually only 
added when they have inadequate control despite use of these drugs.
Pharm acologic Therapy o f Blood Glucose -  Recom m endations
If the desired level of glycaemic control is not reached after several months of lifestyle 
intervention, the patient should be started on drug therapy.
A sulphonylurea is the first line choice for those whose weight is normal or only 
modestly increased. Conversely, markedly obese patients should be started on metformin 
as a first line agent.
Patients who are underweight, are losing weight or are ketotic should be started on 
insulin regardless of age. It is important to consider the possibly of Type I Diabetes in 
this group, as 25% of Type I Diabetics present after the age of 35 (Leslie and Elliott
1994).
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Since most of the available agents lower blood glucose by around 20%, patients whose 
degree of glycaemic control is more than 20% above their goal will probably require 
combination drug therapy. In addition the progressive nature of Type II Diabetes will also 
tend to mandate use of combination therapy if glycaemic targets are to be met. Analysis 
of UKPDS found that 50% of patients originally controlled with a single drug require the 
addition of a second drug after three years; by nine years 75% of patients needed multiple 
therapies to achieve the target HbAlc (Turner et al 1999).
The therapeutic options for patients who fail initial therapy with an oral hypoglycaemic 
drug are:
Add a second drug
- Add insulin
- Discontinue the drug and switch to insulin.
There is no consensus about which option is most effective. The role of insulin in this 
setting is the basis of the systematic review to follow.
Metformin plus Sulphonylureas
This combination may be tried in patients initially treated with a sulphonylurea who 
prefer to avoid insulin injections. Hermann et al (1994) evaluated the use of these drugs 
alone and in combination. Either drug alone lowered HbAlc by 0.9 to 1.3%. The highest 
dose combination achieved a mean fall in Hblc of 2.2%. Similar results were reported by 
the US Multicentre Metformin Study Group (DeFronzo and Goodman 1995).
A subanalysis of UKPDS (UKPDS 34 1998) suggested that the early addition of 
metformin to sulphonylurea therapy may increase the risk of diabetes-related death. 
These results warrant further study before firm conclusions can be made.
Metformin plus a Thiazolidinedione
Patients who fail initial therapy with metformin may benefit from the addition of a 
thiazolidinedione. Metformin and thiazolidinediones both increase insulin sensitivity, but
they act in different ways. Fonseca et al (2000) established this to be an efficacious 
combination as previously stated.
Thiazolidinedione plus a Sulphonylurea
This combination may be used in whom metformin is contra-indicated. Kipnes et al 
(2001) established this to be an efficacious as previously stated.
Alpha-glucosidase Inhibitors (Acarbose)
Acarbose can reduce HbAlc slightly in combination with any other from of therapy. Side 
effects have limited its use. It may be tried in people who have wide swings in blood 
glucose concentrations after meals.
Triple Oral Therapy
In patients not adequately controlled on two oral agents, switching to insulin is probably 
more effective than adding a third agent. Schwartz et al (2003) studied 188 Type II 
Diabetics with inadequate control on two oral agents. They were randomly assigned to 
either the addition of a third agent or to be switched to metformin plus twice-daily 
insulin. At the end of study (week 24 of therapy), HbAlc and fasting plasma glucose 
values showed comparable decreases in the two treatment groups. However, a total of 10 
of the 98 subjects randomised to triple oral therapy (10.2%) who failed to improve 
sufficiently were switched to insulin therapy. An additional four subjects dropped out of 
the oral treatment group due to adverse events felt to be potentially drug related. 
Furthermore, cost analysis determined that insulin plus metformin (mean cost 3.20 
dollars/day) provided efficacy equal to that of a triple oral drug regimen (10.40 
dollars/day).
Insulin Therapy Alone and In Combination With Drug Therapy
The evidence supporting insulin therapy alone and in combination with oral agents shall 
be addressed in the systematic review to follow.
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O v e r v ie w  o f  I n s u l in  T h e r a p y
P re p a ra t io n  In su lin  type
Onset of Maximum Duration of 
action effect (h) action (h)
N e w  i n s u l i n  a n a l o g u e s  
Rapid-acting analogues
Humalog Lispro 15 min 1-2 3.5-4.5
NovoRapid Aspart 10- 
20 min
1-3 3-5
Biphasic analogue mixtures
Humalog Mix25 Lispro + lispro protamine 15 min 2 24
suspension
NovoMix 30 Aspart + aspart protamine 10- 1-4 24
crystallised 20 min
Long-acting analogues
Lantus Glargine 1-2 h 6 +^ 24 +
Not yet named Detemir 1-2 h 6-8 20
C o n v e n t i o n a l  h u m a n  i n s u l i n s
Short-acting insulins
Actrapid Neutral 30 min 2.5-5 8
Humulin R 30 min 2-4 6-8
Intermediate-acting insulins
Humulin NPH Protamine suspension lh 4-10 16-18
Protaphane 1.5 h 4-12 24
Humulin L Zinc suspension (lente) 2 h 6-12 24
Monotard 2.5 h 7-15 22
Long-acting insulins
Humulin UL Microcrystalline zinc 2 h 6-20 24 +
Ultratard suspension (ultralente) 4 h 8-24 28
Biphasic mixtures
Humulin 30/70 Mixture of a neutral insulin 30 min 2-12 16-18
Mixtard 30/70 and a Protarnine suspension 30 min 2-12 24
Humulin 20/80 30 min 1-9.5 17-19
Mixtard 20/80 30 min 2-8 24
Humulin 50/50 30 min 2-12 16-18
Mixtard 50/50 30 min 4-8 24
Fig 1 -  Available Insulin Preparations
Taken from Couper J., Prins J. MJA 2003; 179 (8): 441-447
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Types of Insulin
Insulins can be divided into four categories according to their duration of action:
1. Rapid-Acting Insulin
To produce an insulin preparation with a faster onset and shorter duration than regular insulin, 
modifications have been made to the insulin molecule to prevent it from forming dimers and 
other complexes that slow absorption and delay action (Barnet and Owens 1997). Insulin lispro 
(Humalog) and insulin aspart (NovoRapid) do not self-aggregate in solution as regular insulin 
does. Insulin lispro differs from human insulin by an amino acid exchange of lysine and proline 
at positions 28 and 29 (see figure 2). Insulin aspart is created by the substitution of aspartic acid 
for proline at position 28. These monomeric insulins have an onset of action within 5-15minutes, 
peak action at 30-90 minutes and a duration of action of 2-4 hours (Howey et al 1994 and Home 
et al 1998). The rapid onset of action and short duration makes these agents useful as ‘prandial’ 
or ‘bolus’ insulin to be injected at mealtimes.
Fig 2 -  Structure of Insulin Lyspro
Taken from Boyages S. M JA  1999; 170: 349-350
2. Short-Acting Insulin
Regular human insulin has a delay to onset of action of 30-60 minutes, a peak action of 2-4 hours 
and an duration of action of up to 8 hours when administered subcutaneously. Patients are 
instructed to inject regular insulin 20-30 minutes prior to meals to match insulin availability and 
carbohydrate absorption.
3 . I n t e r m e d i a t e - A c t i n g  I n s u l i n
Neutral protamine Hagedorn (isophane insulin; NPH) insulin is slowly absorbed due to the 
addition of protamine to regular insulin. It has onset of action in 2-4 hours, peak at 4-10 hours 
and a duration of action of 10-16 hours. Regular insulin bound to zinc, Lente insulin, has a 
slightly longer effective duration. Lente and NPH are commonly used as twice daily basal 
insulins. They can also be mixed with soluble insulins, essentially retaining the properties of the 
two components, although there may be some blunting of the initial effect of soluble insulin 
component (especially on mixing with protamine zinc insulin). Lispro protamine suspension and 
aspart protamine crystallised are also available and are functionally equivalent to NPH; however, 
they are only available as biphasic analogue mixtures.
4 . L o n g - A c t i n g  I n s u l i n
Ultralente is a suspension of insulin in the form of a complex obtained by the addition of a 
suitable zinc salt. It is absorbed slowly in its zinc crystalline form. The new insulin analogue, 
insulin glargine, is modified human insulin that forms a microprecipitate in the subcutaneous 
tissue. It is released slowly with a peakless delivery of about 20-24 hours in most patients
The Insulin Analogues
In the past, the pharmacokinetic characteristics of insulin preparations have been modified by 
mixing with substances that delay absorption (eg, protamine and zinc) and by varying crystal 
size. Recombinant DNA technology has now made possible the creation of analogues of human 
insulin with altered pharmacokinetic characteristics. These analogues allow insulin to be 
delivered in a fashion that more closely resembles normal physiology.
R a p i d - a c t i n g  a n a l o g u e s
The rapid-acting insulin analogues insulin lispro and insulin aspart have the following 
advantages:
i) Reduction of postprandial increases in blood glucose concentration, because 
insulin delivery follows the rise in blood glucose after eating more closely. 
Anderson et al (1997) found that insulin lispro resulted in a significant lowering 
of one and two hour postprandial blood glucose concentrations (by 1.3 and 
2.0mmol/L) compared with regular insulin in a study of 1008 patients with Type I 
Diabetes.
ii) Reduced frequency of hypoglycaemia, because of their shorter duration of action. 
Consequent reduced need to snack. A meta-analysis in Type I Diabetes showed 
the rate of severe hypoglycaemia to be 3.1% with insulin lispro compared with 
4.4% with regular insulin (p=0.024) (Brunelle et al 1998).
iii) Increased convenience, because their very rapid onset of action allows them to be 
injected immediately before meals or even after eating.
iv) Rapid onset of action is not blunted by mixing with NPH insulin, as is that of 
regular insulin (Joseph et al 1998).
They do however have the following disadvantages:
i) Their shorter duration of action can lead to preprandial hyperglycaemia (Torlone 
et al 1996).
ii) Low basal serum insulin concentrations may mandate increased doses of 
intermediate- or long-acting insulin (Lalli et al 1999).
iii) Unknown teratogenicity and long-term safety profile.
iv) Higher cost.
Long-acting analogues
Insulin glargine was created by substituting and adding amino acids to the insulin molecule. The 
yet to be licensed insulin detemir was created by adding a fatty acid chain, which enhances 
binding to albumin. In contrast to NPH or Lente insulin, the time action profile for insulin has 
virtually no peak (see figure 3). A flat dose profile with a low peak of action provides more 
predictable background control than the intermediate-acting insulins, without the unwanted 
peaks of action around lunchtime and during the night.
180
■2 140
lOO
NPH human insulin
Tim*, hours
Fig 3 -  Time-action profile of NPH and insulin glargine
Serum insulin concentrations after subcutaneous injection of
0.4u/kg body weight of insulin glargine or NPH human insulin 
on 2 different study days in 15 normal subjects. Data from 
Heinemann L. et al. Diabetes Care 2000; 23:644
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In su lin  Reg im ens
O n c e - d a i l y  r e g i m e n s
For patients with Type II Diabetes who are not controlled by diet and oral hypoglycaemic drugs, 
the choice is between adding insulin or discontinuing the drugs and treating with insulin alone. In 
either case, a once-daily dose of intermediate or long-acting insulin may be sufficient.
For patients treated with insulin alone, a once-daily regimen may be effective, although serum 
insulin concentrations are more stable in patients taking two doses daily, even when the insulin is 
long-acting ultralente insulin (Holman and Turner 1985). Taylor et al (2000) compared once- 
daily ultralente insulin with twice-daily NPH insulin in a 6-month crossover study of 79 patients 
with Type II Diabetes. The NPH regimen was associated with improved glucose control (HbAlc
9.1 vs 9.7%), fewer hypoglycaemic episodes (171 vs 220) and greater patient satisfaction. Poorer 
glycaemic control in the ultralente group related primarily to higher evening glucose levels.
For combination NPH or ultralente insulin and drug therapy, it is preferable to take insulin at 
bedtime (Yki-Jarvinen et al 1992). The rationale for this regimen is that, by suppressing hepatic 
glucose production overnight, the patient starts the day with a lower fasting blood glucose and 
can retain the convenience of oral therapy during the day while minimising total insulin 
requirements.
Insulin glargine may represent the best choice for once daily therapy in patients with Type II 
diabetes. Compared to NPH or ultralente insulin given at bedtime to supplement oral therapy, 
insulin glargine achieves similar glycaemic control, with less hypoglycaemia and possibly less 
weight gain (Yki-Jarvinen, Dressier and Ziemen 2000 and Rosenstock et al 2001).
Contrary to NPH and ultralente, insulin glargine may be most appropriately given in the morning 
in patients on an oral agent. Fritsche et al (2003) found that a morning dose of insulin glargine 
lowered HbAlc by 1.24%, compared to 0.96% with a bedtime dose, and 0.84% with bedtime 
NPH, in a study of 695 patients with Type II Diabetes also receiving glimepiride. Nocturnal 
hypoglycaemia was also less frequent with morning insulin glargine (17%) and bedtime insulin 
glargine (23%), than with bedtime NPH (38%).
- 5 9 -
T w i c e - d a i l y  r e g i m e n s
Twice daily NPH or lente insulin may provide adequate control in patients with Type II 
Diabetes. If postprandial rises in blood glucose are a concern, then either oral drugs should be 
continued or a short acting insulin added. This may be achieved with twice daily injection 
(before breakfast and before dinner) o f a biphasic insulin mixture, which results in four peaks of 
insulin action (see figure 4).
#
Fig 4 -  Effect of twice-daily biphasic insulin regimen
Taken from McCulloch D. (2003). UpToDate Clinical Reference Library -  Basic 
insulin regimens in diabetes mellitus USA. (Internet). Available from 
http://www.uptodate.com (accessed December 2003).
In practice, when insulins are mixed the peaks of the individual profiles tend to merge somewhat. 
This effect is most prominent with zinc-containing insulin preparations such as lente or ultralente 
insulin (Colagiuri and Villalobos 1986). Because of variability in peak effect, it may be more 
difficult to achieve excellent glycaemic control with premixed insulins. The morning dose of 
intermediate-acting insulin may not be sufficient to prevent a post-lunchtime rise in blood sugar. 
Similarly, the intermediate-acting insulin administered before the evening meal may not be 
sufficient to achieve an acceptable fasting blood sugar the next morning unless a larger dose is 
given, which increases the risk of nocturnal hypoglycaemia. Thus, if near normoglycaemia is the 
goal it may be preferable to keep basal insulins separate from pre-meal insulins to enable them to 
be adjusted independently.
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B a s a l - b o l u s  r e g i m e n
Due to the limitations of twice daily biphasic insulin injections highlighted above, a proportion 
of people will require conversion to a 3-4 injections daily regimen. For intensive therapy we 
must aspire to mirror a physiological insulin secretion profile -  this can only be achieved with a 
regime consisting of an intermediate- or long-acting insulin to provide a basal rate and then 
bolus/pre-meal injections of rapid- or short-acting insulin. It is preferable to give the 
intermediate- or long-acting insulin into a site (leg or buttock) where absorption is slow and the 
pre-meal bolus into the abdomen from which insulin is absorbed more rapidly.
C o n t i n u o u s  s u b c u t a n e o u s  i n s u l i n  i n f u s i o n  ( i n s u l i n  p u m p )
Continuous subcutaneous insulin therapy has been used successfully in both research studies like 
the DCCT (1993) and in large clinical practices (Mecklenburg et al 1985). Only fast-acting 
insulin (regular, or monomeric analogues like lispro and aspart) is used with continuous therapy. 
The background insulin is supplied in the form of a basal infusion (comprising about 60 percent 
of the total daily dose) with pre-meal bolus doses given to minimize postprandial 
hyperglycaemia. Patients with Type II Diabetes may be considered for pump use if they 
experience severe hypoglycaemia and wide fluctuations of glucose levels.
Insulin pump therapy may achieve slightly better glycaemic control than multiple daily injections 
and reduces hypoglycaemic events (Pickup, Mattock, Kerry 2002). There are, however, 
disadvantages to continuous therapy. The costs of the pump and supplies are higher than those of 
ordinary syringes and needles. Many patients who use pumps also complain that the treatment is 
awkward, uncomfortable, embarrassing, or unpleasant. Voluntary termination of this pump 
therapy is common, occurring in one study in 29 percent of 177 patients within five years 
(Guinn, Bailey and Mecklenburg 1988).
Summary
There is currently no consensus as to which insulin formulations or what regimen to use in Type 
II Diabetes. There is also uncertainty as to how to most appropriately combine insulin therapy 
with oral drugs. In the systematic review to follow I have endeavoured to ascertain just what 
evidence exists supporting the use of various formulations and regimens, what are the potential 
advantages and disadvantages, and what is the most appropriate way of combining insulin 
therapy with oral therapy.
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System atic Review Research Protocol 
The Question
The purpose of this dissertation is to address one fundamental question:
“How should we best use insulin in the management of Type II Diabetes?”
In reality, in answering this question I am called upon to address a multitude of 
subsidiary questions including the following?
“When should insulin be used in Type II Diabetes?”
“What different formulations are available?”
“What are we hoping to achieve with insulin therapy?”
“What regimen is most effective in achieving this aim?”
“What are the advantages/disadvantages of each formulation/regimen?”
“What are the risks of insulin therapy?”
“Should insulin be used alone or in combination with oral drug therapy?”
The study factor ‘insulin’ is not a single agent, but a number of different formulations 
that can be used in a number of different combinations (or regimens). This adds a 
significant increased complexity to the question, as it necessitates the comparison of 
multiple different treatment regimens.
The study population is fairly clearly defined, that being Type II Diabetes. That said, 
diagnostic criteria do vary slightly between different countries and have evolved 
somewhat with the passage of time. There will also be significant differences between the 
overall levels of glycaemic control among subjects in different studies, which may pose 
difficulties in interpretation, i.e. One study may examine subjects with a pre-treatment 
median HbAlc of 12% while another study may have a median HbAlc of 8% - one 
would imagine each population may respond differently to the same 
treatment/intervention.
The most important outcomes in assessing a treatment in Type II Diabetes are rates of 
complications (microvascular and macrovascular) and mortality data. However, due to 
the long-term nature of these outcomes, most studies are of too short duration to 
demonstrate statistically significant differences. In Chapter 2, I detailed the evidence 
supporting normoglycaemia as a therapeutic target. With this in mind, I shall look at 
HbAlc and fasting blood glucose levels as surrogate markers of improved glycaemic 
control, accepting that it is now well established that improved glycaemic control is 
associated with better outcomes. It is also established that tighter glycaemic control 
increases the risk of hypoglycaemic events, so this will also be an important endpoint of 
interest. Insulin therapy is also frequently associate with weight gain, so where reported I 
shall also collate data on weight changes with different therapies.
Finding Relevant Studies
Finding all the relevant studies is not easy. There are currently over 22000 journals in the 
biomedical literature and MEDLINE indexes only 3700 of these (NHMRC 2000). To 
maximise my data capture I shall employ the following strategies:
literature search in MEDLINE from 1966 to December 2003 (see Appendix 1) 
literature search in EMBASE from 1980 to December 2003 (see Appendix 2) 
letter writing to the UK and Australian divisions of the three key 
pharmaceutical companies involved in insulin therapy requesting unpublished 
data (see Appendix 7 and Appendix 8)
- bibliographical searching for papers missed by the above strategies
Because of their unique ability to control for confounders, known or unknown, 
randomised controlled trials (RCT’s) generally provide the best evidence of efficacy for 
interventions. I shall therefore restrict my literature search to RCT’s. Previous systematic 
reviews shall also be evaluated to ensure I have not missed any important trials with my 
search strategy.
Study Selection
I shall execute the MEDLINE and EMBASE searches as detailed in Appendices 1 and 2. 
Due to my limitations with respect to accessing translations, I shall limit my search to 
only English language papers. I shall also include only those studies with an abstract 
available on the OVID -  NHS KA24 site that serves as my access to MEDLINE and 
EMBASE.
I shall then peruse the abstracts of studies yielded by the above searches and select all 
those studies that meet the following inclusion criteria:
Subjects with Type II Diabetes
- Random treatment allocation
- Involves use of insulin (alone or in combination with oral hypoglycaemic 
drugs)
Minimum of 4 weeks treatment duration 
Minimum of 10 patients in each arm 
Reports glucose measurements or HbAlc 
AND rates of hypoglycaemia
I shall tabulate the reason for exclusion of studies yielded by the literature search but not 
included in further analysis according to the following criteria:
1. Not a randomised controlled trial
2. Study outcomes don’t match
3. Wrong patient group
4. Insufficient patient numbers
5. Inadequate study duration
6. Duplicate study
7. Irrelevant treatment comparison (includes unlicensed treatments)
I will then endeavour to access full-text versions of all the included studies using the 
following sources:
- OVID-NHS KA24 site
- University of Surrey e-journal on-line access
- University of Surrey distance learning librarian
- University of Sydney library collection
Web based journal access (where available on-line free of charge)
- Prince of Wales Hospital, NSW Australia -  Medical library collection 
Studies not available from one of the above sources will be excluded from further 
analysis.
I shall conduct a further bibliographical search of the eligible studies available in full text 
looking for any relevant studies my searches may have missed.
Additional eligible studies may become available from my written request to the key 
pharmaceutical companies (see Appendices 3 and 4). These studies shall be subject to the 
same inclusion criteria as the others.
Anticipated Difficulties
Despite employing the strategies above, there may still be an inadequate evidence base to 
allow reliable conclusions to be drawn; The National Institute of Clinical Excellence 
(NICE 2002) asserts:
“T h e r e  i s  n o  d i r e c t  e v i d e n c e  t o  s u p p o r t  t h e  u s e / c h o i c e  o f  a n y  o n e  i n s u l i n  
t y p e  o r  r e g i m e  o v e r  a n o t h e r ”
“L o c a l  e x p e r i e n c e ,  p a t i e n t  p r e f e r e n c e  a n d  r e l a t i v e  c o s t s  s h o u l d  i n f o r m  t h e  
c h o i c e  o f  i n s u l i n  t y p e  a n d  r e g i m e n  a s  t h e r e  i s  l i t t l e  r e s e a r c h  e v i d e n c e  in  
t h i s  a r e a  ”
I am hopeful that new data may have emerged since NICE conducted their review. 
Furthermore, I suspect their interpretation of the evidence may differ from my own, 
particularly as they may be influenced by the funding implications of their conclusions.
Critical Appraisal -  Assessment of Study Quality
“Quality assessment of individual studies that are summarised in systematic reviews is 
necessary to limit bias in conducting the systematic review, gain insight into potential 
comparisons, and guide interpretation of findings” (Cochrane Reviewers’ Handbook 
4.2.0)
Numerous quality assessment methods have been utilised but the optimal use of quality 
items and scales is still not clear (Moher et al 1995). Because there is no ‘gold standard’ 
for the true validity of a trial, it is difficult to validate any proposed scoring system. 
Cochrane advises that none of the currently available scales can be recommended without 
reservation and that “it is preferable to use simple approaches for assessing validity that 
can be fully reported” (Cochrane Reviewer’s Handbook 4.2.0). Guidance from NHMRC 
(2000) recommends that items be restricted generally to those that have been shown to 
affect the results of trials. For these reasons I have elected to adopt the following quality 
appraisal checklist (taken from NHMRC 2000):
1. Method of treatment assignment
a. Correct, blinded randomisation method described 
OR randomised, double-blind method stated 
AND group similarity documented
b. Blinding and randomisation stated but method not described 
OR suspect technique
c. Randomisation claimed but not described and investigator not blinded
d. Randomisation not mentioned
2. Control of selection bias after treatment assignment
a. Intention to treat analysis AND full follow-up
b. Intention to treat analysis AND <15% loss to follow-up
c. Analysis by treatment received only OR no mention of withdrawals
d. Analysis by treatment received AND no mention of withdrawals
OR >15% withdrawals/loss to follow-up/post-randomisation 
exclusions
Blinding
e. Blinding of outcome assessor 
AND patient and care-giver
f. Blinding of outcome assessor 
OR patient and care-giver
g. Blinding not done
3. Outcome assessment (if blinding was not possible)
a. All patients had standardised assessment
b. No standardised assessment or not mentioned
Data Synthesis
The complexity of comparing multiple treatment regimens poses challenges in terms of 
data synthesis. The desire to ‘pool data’, where appropriate, must be offset against 
apparently small differences in treatment regimens or study populations that may have 
large impacts on outcomes. It is my expectation that it will be difficult to synthesise the 
data in a quantitative fashion. I will critically appraise the available evidence and 
synthesise the findings qualitatively. This methodology is supported by guidelines from 
the National Health and Medical research Council guidelines (NHMRC 2000), which 
state that quantitative synthesis of the data “is neither necessary nor sufficient to make a 
review systematic.” However, wherever possible, I will also quantitatively synthesise 
data the mean change in HbAlc and weight changes as these are fairly consistently 
reported across trials.
Data from the publications will be compiled in table form as this will facilitate my 
grouping and understanding of the evidence. Trials evaluating similar treatment regimens 
or agents will be grouped together to allow results to be compared more readily. Data 
from the tables will then be synthesised in order to make specific evidenced based 
recommendations about the various regimens.
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Literature search results
The following flow diagram gives an overview of the yield of the literature search and 
eligible studies.
Further details of the search methodology, yield and complete lists of eligible studies 
are presented as appendices to this dissertation as follows:
Appendix 1 
Appendix 2 
Appendix 3 
Appendix 4 
Appendix 5 
Appendix 6 
Appendix 7 
Appendix 8
Medline search string 
Embase search string
Medline eligible studies after title and abstract review 
Medline excluded studies after title and abstract review 
Embase eligible studies after title and abstract review 
Embase excluded studies after title and abstract review 
Letter requesting unpublished data
List of pharmaceutical companies approached for unpublished
data
Appendix 9: Final list of eligible studies after quality appraisal inclusive of
additional eligible studies identified by bibliographical search and written 
requests to key pharmaceutical companies
F l o w  of eligible studies
As per my research protocol I have undertaken a quality assessment of each included 
study using the following quality appraisal checklist (NHMRC 2000)1:
1. Method of treatment assignment
a. Correct, blinded randomisation method described 
OR randomised, double-blind method stated 
AND group similarity documented
b. Blinding and randomisation stated but method not described 
OR suspect technique
c. Randomisation claimed but not described and investigator not blinded
d. Randomisation not mentioned
2. Control of selection bias after treatment assignment
a. Intention to treat analysis AND full follow-up
b. Intention to treat analysis AND <15% loss to follow-up
c. Analysis by treatment received only OR no mention of withdrawals
d. Analysis by treatment received AND no mention of withdrawals
OR >15% withdrawals/loss to follow-up/post-randomisation 
exclusions
3. Blinding
a. Blinding of outcome assessor 
AND patient and care-giver
b. Blinding of outcome assessor 
OR patient and care-giver
c. Blinding not done
Quality Assessment of Included Studies
4. Outcome assessment (if blinding was not possible)
a. All patients had standardised assessment
b. No standardised assessment or not mentioned
Study Method of
treatment
assignment
Control of 
selection bias 
after
treatment
assignment
Blinding Outcome
assessment
Ml - HOE A D C A
901/2004 Study Double-blind ITT analysis Insulin glargine (clear
Investigators randomisation but 25% drop solution) vs NPH
Group (2003) via telephone outs (cloudy solution)
M2 -  Wulffele et al B B A A
(2002) Double-blind 
randomisation 
stated but 
slightly older 
metformin 
group
ITT analysis 
with 10% drop 
outs
Insulin plus metformin 
vs Insulin plus matched 
placebo
M3 -  Herz et al A D C A
(2003) Randomisation 
stated and cross­
over design and 
groups 
comparable
ITT analysis 
(1 dose 
required) but 
16% drop outs
Open-label comparison 
of Humalog Mix 25 and 
Mixtard 30/70
M4 -  Strowig et al A. C C A
(2002) Random 
assignment with 
sealed 
sequentially 
marked 
envelopes
Analysis by 
treatment 
received 
(88/92)
Insulin +/- metformin or 
troglitazone
M5 -  Herz et al A B C A
(2002) Randomisation 
stated and cross­
over design
ITT analysis 
with 10% drop 
outs
Open-label comparison 
of insulin 30/70 and 
lispro Mix25
M6-UKPDS 33 A B C A
(1998) Random 
assignment with 
centrally 
produced, 
computer 
generated 
allocations in 
sealed opaque 
envelopes.
ITT analysis 
with 4.4% 
drop outs
Unblinded comparison 
of multiple different 
therapies
M 7- UKPDS 49 A B C A
-75-
(1999) Random 
assignment with 
centrally 
produced, 
computer 
generated 
allocations in 
sealed opaque 
envelopes
ITT analysis 
with 4.4% 
drop outs
Unblinded comparison 
of multiple different 
therapies
M8 -  Schwartz et
al (1998)
A
Double-blind 
randomisation 
stated and 
groups 
comparable
B
ITT analysis 
(1 dose and 1 
follow-up visit 
required) with 
10% drop outs
A
Placebo vs troglitazone 
200mg or 600mg 
(single-blind placebo 
run-in)
A
M9 -  Raskin et al
(2001)
A
Randomisation 
codes generated 
with “an internal 
software 
system” and 
groups 
comparable
D
ITT analysis 
(required one 
postbaseline 
measurement) 
but 20% drop 
outs
A
Placebo vs rosiglitazone 
2mg bd or 4mg bd 
(single-blind placebo 
run-in)
A
M10 -  Rosenstock
et al (2001)
A
Randomisation 
claimed, but not 
described. 
Groups seem 
comparable
B
ITT analysis 
(required one 
postbaseline 
measurement) 
with 10% drop 
outs
C
Insulin glargine (clear 
solution) vs 
NPH (cloudy solution)
A
M il-H O E  
901/3002 Study 
Group (2000)
A
Randomisation 
via telephone to 
an independent 
agency
B
ITT analysis 
with 14% drop 
outs
C
Insulin glargine (clear 
solution) vs 
NPH (cloudy solution)
A
Ml 2 -  Boehm et al
(2002)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
B
ITT analysis 
(required drug 
exposure plus 
any efficacy 
data) with 8% 
drop outs
C
Insulin 30/70 30mins 
pre-meal vs. 
Insulin aspart 30 lOmins 
pre-meal
A
Ml3 -  Zargar et al
(2002)
B
Randomisation 
by consecutive 
allocation to one
C
Analysis by 
treatment 
received with
C
i) Twice daily insulin 
regimen alone
ii) Twice daily insulin +
A
of four groups — 
suspect 
technique
10% drop outs glibenclamide
iii) Morning insulin + 
glibenclamide
iv) Evening insulin + 
glibenclamide
M14 -  Rosenstock A B A A
et al (2002) Randomisation 
claimed but not 
described. 
Groups seem 
comparable
ITT analysis 
with 12% drop 
outs
i) Insulin plus 
pioglitazone 15mg
ii) Insulin plus 
pioglitazone 30mg
iii) Insulin plus matched 
placebo
Ml 5 -  Herz et al A B C A
(2002) Randomisation 
claimed but not 
described. 
Groups seem 
comparable
ITT analysis 
with 11% drop 
outs
Open-label comparison 
of Mix75/25 and 
glybuiide
Ml 6 -  Hermann et A B A A
al (2001) Double-blind 
randomisation 
performed by 
centre in blocks 
of four and 
groups 
comparable
ITT analysis 
with 14% drop 
outs
Insulin plus metformin 
vs Insulin plus matched 
placebo
Ml 7 -  Ross et al A B C A
(2001) Randomisation 
claimed but not 
described. 
Groups seem 
comparable.
ITT analysis 
with 3% drop 
outs
NPH plus Humulin R 
30mins pre-meal vs 
NPH plus Humalog 
5mins pre-meal
Ml 8 -  Roach et al A B C A
(2001) Randomisation 
lists computer 
generated by 
country and 
groups 
comparable
ITT analysis 
(required one 
post-baseline 
efficacy 
measurement) 
with 10% drop 
outs
Open-label comparison 
of Humalog Mix25 and 
glyburide
Ml 9 -  Ponssen et A A A A
al (2000) Double-blind 
randomisation 
stated and
ITT analysis 
(required 1 
dose of
Twice-daily Insulin 
30/70 + metformin or 
placebo
groups 
comparable and 
cross-over 
design
metformin) 
and full 
follow-up
M20 -  Guvener 
and Gedik (1999)
B
Double-blind 
randomisation 
stated but not 
described and 
older acarbose 
group
C
Analysis by 
treatment 
received with 
5% patients 
lost to follow 
up
A
Double-blind method 
claimed but not 
described. Acarbose vs 
gliclazide
A
M21 -  Aviles-Santa 
et al (1999)
A
Double-blind 
randomisation 
stated and 
groups 
comparable
B
ITT analysis 
(required one 
post-baseline 
HbAlc 
measurement) 
with 7% post­
randomisation 
drop outs
A
Insulin + metformin vs 
Insulin + matched 
placebo
A
M22 -  Standi et al
(1999)
A
Double-blind 
randomisation 
stated and 
groups 
comparable
C
Analysis by 
treatment 
received only 
with 10% 
excluded from 
efficacy 
analysis
A
Combination 
Insulin/Sulphonylurea 
therapy + acarbose or 
matched placebo
A
M23 -  Abraira et
al (1998)
A
Blinded 
randomisation 
and group 
similarity 
documented in 
other papers
B
ITT analysis 
with 8% drop 
outs
C
Unblinded comparison 
of stepwise intensive 
therapy and standard 
treatment with insulin
A
M24 -  Relimpio et
al (1998)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
D
Analysis by 
treatment 
received and 
22% drop-outs
C
Insulin (dose increase) 
vs Insulin + metformin
A
M2 5 -  Niazi and 
Muzaffar (1998)
C
Selection of 
patients was ‘at 
random’ and 
they were
D
Basis of 
analysis is 
unclear and 
50% of the
C
Sulphonylurea + 
metformin vs 
Sulphonylurea + bedtime 
NPH
A
‘divided’ into 
parallel groups. 
Investigator not 
blinded
insulin group 
(9/18) dropped 
out after 8 
weeks
M26 -  Tovi et al
(1998)
A
Randomisation 
using a 
‘ random-number 
table’
C
Analysis by 
treatment 
received only 
with 12.5% 
excluded from 
analysis
C
Insulin vs 
continued sulphonylurea 
in patients with 
secondary oral failure
A
M27 -  Buse et al
(1998)
A
Double-blind 
randomisation 
stated and 
groups 
comparable
B
ITT analysis 
(216/222 - 
?eriteria) 
withl3% drop 
outs
A
Troglitazone 200mg, 
400mg or matched 
placebo (single-blind 
placebo run-in)
A
M2 8 -  Penfornis 
and Millot (1998)
A
Centralised 
randomisation 
by telephone
C
Analysis by 
treatment 
received with 
6% excluded 
from final 
analysis
C
Open comparison of 
inpatient vs outpatient 
initiation of insulin 
therapy
A
M29 -  Birkeland et
al (1996)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
B
ITT analysis 
with 6% drop 
outs. N.B. 
61% of SU 
patients had to 
be given 
insulin
C
Open-label comparison 
of insulin and 
glibenclamide
A
M30 -  Fanghanel
et al (1996)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
C
Analysis ?by 
treatment 
received with 
3% drop outs
C
Open-label comparison 
of insulin and metformin
A
M31 -  Ravnik- 
Oblak and Mrevlje
(1995)
A
Randomisation 
stated and cross­
over design
B
ITT analysis 
with 11% drop 
outs
C
Unblinded -  Insulin +/- 
Glibenclamide (should 
have used GB placebo!)
A
M32 -  Calle- 
Pascual et al (1995)
B
Consecutive 
subjects were 
allocated
A/C 
No reported 
drop-outs with 
suggested ITT
C
i) Bedtime lente insulin
ii) Sulfonylurea + 
metformin
A
sequentially into 
three groups -  
suspect 
technique.
analysis (not 
explicit)
iii) Sulfonylurea + 
acarbose
M33 -  Ohkubo et
al (1995)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
B
ITT analysis 
with 7% drop 
outs
C
Open label comparison 
of conventional insulin 
therapy (1-2 daily 
injections) vs multiple 
insulin injection therapy 
(3 or more daily)
A
M34 -  Landstedt- 
Hallin et al (1995)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
B
?ITT analysis 
with 5% drop 
outs
C
Open label comparison 
of glibenclamide plus 
preprandial regular 
insulin vs glibenclamide 
plus bedtime NPH
A
M3 5 -  Coniff et al
(1995)
A
Double-blind 
randomisation 
stated and 
groups 
comparable
C
Analysis by 
treatment 
received with 
5% drop outs
A
Insulin + acarbose vs 
Insulin plus matched 
placebo
A
M36 -  Chow et al
(1995)
B
Patients were 
consecutively 
and alternately 
assigned 
according to 
time of 
recruitment 
from single 
centre -  suspect 
technique! 
Groups seem 
comparable.
C
Analysis by 
treatment 
received with 
4% excluded 
from final 
analysis
C
Open -label comparison 
of insulin monotherapy 
vs insulin plus OHA
A
M37 -  Riddle et al
(1992)
A
Double-blind 
randomisation 
performed by 
manufacturer
A
ITT analysis 
and full 
follow-up
A
Suppertime pre-mixed 
70NPH/30% regular 
insulin + glyburide lOmg 
mane or matched 
placebo
A
M3 8 -  Paterson et
al (1991)
B
Random 
assignment 
stated, but 
method not 
described and 
some 
dissimilarities 
between groups
A/C 
No reported 
drop-outs with 
suggested ITT 
analysis (not 
explicit)
C
Bedtime ultralente 
insulin vs 3-4 times daily 
Actrapid
A
M39 -  Karlander 
et al (1991)
EXCLUDED-  
DUPLICATE 
OF M51 -  
Gutniak et al 
(1987)
M40 -  Klein W. 
(1991)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
D
Analysis by 
treatment 
received and 
30% drop-outs
C
Sulphonylurea + 
metformin vs 
sulphonylurea + insulin
A
M41 -  Groop and 
Widen (1991)
A
“Block- 
randomisation” 
stated and 
groups 
comparable
A/C 
No reported 
drop-outs with 
suggested ITT 
analysis (not 
explicit)
C
i) Twice daily mixed 
insulin vs
ii) Glibenclamide + 
metformin vs
iii) 6/52 intensive insulin 
followed by 
glibenclamide alone
A
M42 -  Sotaniemi et
al (1990)
A
Double blind 
randomisation 
via a “closed 
envelope” and 
cross-over 
design
Al
ITT analysis 
and full 
follow-up
A
OHA + insulin 
(Protaphane) or Insulin- 
placebo
A
M43 -  Simpson et
al (1990)
EXCLUDED -  
INADEQUATE 
PATIENT 
NUMBERS
M44 -  Groop et al
(1989)
A
“Block- 
randomisation” 
stated and 
groups 
comparable
A
ITT analysis 
and full 
follow-up
C
Open-label comparison 
of mixed insulin bd and 
glibenclamide/metformin 
combination
A
M45 -  Lewitt et al
(1989)
A
Double-blind 
randomisation 
stated and cross­
over design
B
ITT analysis 
with 6% drop­
outs
A
Insulin +/- glyburide or 
placebo (cross-over 
design)
A
M46-
Wolffenbuttel et al
(1989)
EXCLUDED-  
INADEQUATE 
PATIENT 
NUMBERS
A
Random 
allocation stated 
and cross-over 
design
AIC 
No reported 
drop-outs with 
suggested ITT 
analysis (not 
explicit)
C
Insulin vs sulphonylurea 
for six months (cross­
over design)
A
M47 -  Casner
(1988)
B
“Block- 
randomisation” 
stated but 
placebo group 
slightly older
D
Analysis by 
treatment 
received and 
23% drop-outs
A
Insulin + glyburide vs 
Insulin plus matched 
placebo
A
M48 -  Lins et al
(1988)
B
Double-blind 
randomisation 
stated but 
placebo group 
younger
A
ITT analysis 
and full 
follow-up 
(9/29 exclude 
pre­
randomisation)
A
Insulin + glibenclamide 
vs Insulin plus matched 
placebo
A
M49 -  Mauerhoff
et al (1986)
B
Random 
allocation stated, 
not described 
and sex 
inequality 
between groups
AIC 
No reported 
drop-outs with 
suggested ITT 
analysis (not 
explicit)
A
Insulin + glibenclamide 
vs
Insulin + placebo
A
M50 -  Reich et al 
(1987)
EXCLUDED -  
INADEQUATE 
PATIENT 
NUMBERS
B
Random 
assignment 
stated, but 
method not 
described and 
some 
dissimilarities 
between groups
A
ITT analysis 
and full 
follow-up
A
Insulin + glyburide vs 
Insulin + placebo
A
M51 -  Gutniak et
al (1987)
EXCLUDED-  
BORDERLINE
B
Random 
assignment 
stated, but 
method not
AIC 
No reported 
drop-outs with 
suggested ITT 
analysis (not
A
Twice daily insulin + 
glyburide vs 
Twice daily insulin + 
placebo
A
PATIENT 
NUMBERS & 
METHODOLOGY 
CONCERNS
described and 
some 
dissimilarities 
between groups
explicit)
M52 -  Holman et
al (1987)
A
Random 
allocation stated 
and cross-over 
design
C
Analysis by 
treatment 
received with 
12% excluded 
from final 
analysis
C
i) sulfonylurea alone
ii) sulfonylurea + 
metformin
iii) sulfonylurea + daily 
ultralente insulin
iv) daily ultralente 
insulin alone
v) ultralente insulin with 
twice daily Actrapid 
(cross-over design)
A
M53 -  Samanta et
al (1987)
A
Randomisation 
using ‘random 
cards’
A/C 
No reported 
drop-outs with 
suggested ITT 
analysis (not 
explicit)
C
Insulin twice daily vs 
Tolbutamide
A
M54 -  Quatraro et
al (1986)
A
Randomisation 
stated and 
groups 
comparable
A/C 
No reported 
drop-outs with 
suggested ITT 
analysis (not 
explicit)
C
Intensive insulin vs 
Insulin + sulfonylurea
A
M55 -  Falko and 
Osei (1985)
A
Double-blind 
randomisation 
stated and 
groups 
comparable
C
Analysis by 
treatment 
received with 
5% excluded 
from final 
analysis
A
Insulin + glyburide vs 
Insulin plus matched 
placebo
A
M56 -  Groop et al
(1985)
A
Randomisation 
stated and cross­
over design
C
Analysis by 
treatment 
received with 
7% excluded 
from final 
analysis
A
Insulin + glibenclamide 
vs
Insulin + matched 
placebo
A
M57 -  Groop et al
(1984)
A
Randomisation 
stated and cross­
over design
A/C 
No reported 
drop-outs with 
suggested ITT
A
Insulin + glibenclamide 
vs
Insulin + matched
A
analysis (not 
explicit)
placebo
El -  Sargin et al
(2003)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
C
Analysis by 
treatment 
received with 
8% drop outs
C
Open-label comparison 
of bedtime NPH plus 
preprandial regular 
insulin vs lunch and 
bedtime NPH plus 
preprandial insulin-lispro
A
E2 -  Raskin et al
(2003)
A
Blinded 
randomisation 
“to the lowest 
available 
randomisation 
number within 
each centre”.
B
ITT analysis 
(required to 
receive some 
study 
medication) 
with 4% drop 
outs (post- 
randomisation 
but prior to 
study 
medication)
C
Open-label comparison 
of continuos insulin 
infusion vs multiple 
daily injection therapy
A
E3 -  Schwartz et al
(2003)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
B
ITT analysis 
(required 1 
dose of study 
medication) 
with 9% drop 
outs
C
Open-label comparison 
of triple oral therapy vs 
insulin 30/70 + 
metformin
A
E4 -  Alvarsson et
al (2003)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
D
Analysis by 
treatment 
received with 
24% drop outs
C
Open label comparison 
of glibenclamide vs 
insulin (Mixtard 30/70 
bd)
A
E5 -  Hwu et al
(2003)
B
Randomisation 
claimed but not 
described. 
Acarbose group 
slightly older
B
ITT analysis 
(required 1 
post-baseline 
HbAlc) with 
9% drop outs
A
Insulin plus acarbose vs 
Insulin plus matched 
placebo
A
E6 -  Stehouwer et
al (2003)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
A/C 
No reported 
drop-outs with 
suggested ITT 
analysis (not 
explicit)
C
Open-label comparison 
of bedtime NPH plus 
glimepiride vs NPH 
twice daily vs Mix 30/70 
bd
A
E7 -  Kelley et al
(1998)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
D
Analysis by 
treatment 
received with 
26% post 
randomisation 
exclusions
A
Insulin plus acarbose vs 
hisulin plus matched 
placebo (single-blind 
placebo run-in)
A
E8 -  Robinson et al
(1998)
A
Randomisation 
stated and cross­
over design
C
Analysis by 
treatment 
received with 
6% drop outs
A
hisulin + metformin vs 
Insulin + matched 
placebo
A
E9-Riddle et al
(1998)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
C
Analysis by 
treatment 
received with 
9% drop outs
A
Insulin (Mix 30/70 bd) 
+ glimeperide vs 
Insulin + matched 
placebo
A
E10 -  Feinglos et al
(1998)
A
Double-blind 
randomisation 
stated and cross­
over design
A/C 
No reported 
drop-outs with 
suggested ITT 
analysis (not 
explicit)
A
Insulin + glipizide vs 
Insulin + matched 
placebo
A
El 1 -  Anderson et
al (1997)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
A/C 
No reported 
drop-outs with 
suggested ITT 
analysis (not 
explicit)
C
Basal insulin + regular 
insulin 30mins pre-meal 
vs. basal insulin + 
insulin lispro 
immediately pre-meal
A
E12 -  Saudek et al
(1996)
B
Randomisation 
stated with 
stratification by 
centre, with a 
balancing 
interval of 4. 
MDI group were 
more
overweight.
C
Analysis by 
treatment 
received with 
13% drop outs
C
Implantable insulin 
pump therapy vs 
multiple daily insulin 
injections
A
El3 -  Clauson et al
(1996)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
B
ITT analysis 
with 5% drop­
outs
C
Intensive insulin (QID) 
vs
bedtime NPH + 
glibenclamide
A
E14 -  Birkeland et 
al (1994) 
EXCLUDED - 
DUPLICATE OF 
M29 (1 YEAR VS 
3 YEAR DATA)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
C
Analysis by 
treatment 
received with 
6% drop outs
C
Insulin vs 
glibenclamide
A
El5 -  Taylor et al A B C A
(1994) Randomisation 
using 
‘independantly 
prepared sealed 
envelopes’, and 
cross-over 
design
ITT analysis 
with 9% drop­
outs
Preprandial Actrapid vs 
Protaphane bd 
(cross-over design)
El 6 -  Giugliano et B A A A
al (1993) Randomisation 
claimed but not 
described. No 
baseline data to 
compare groups.
ITT analysis 
and full 
follow-up
Insulin + metformin vs 
Insulin + matched 
placebo (single-blind 
placebo run-in)
El7 -  Riddle et al A C A A
(1989) Double-blind 
randomisation 
by the drug 
manufacturer 
and cross-over 
design
Analysis by 
treatment 
received with 
5% drop outs
Evening NPH + 
Glyburide vs 
Evening NPH + placebo 
(cross-over design)
El8 -  Tindall et al A A/C C A
(1988) Randomisation 
claimed but not 
described. 
Groups seem 
comparable
No reported 
drop-outs with 
suggested ITT 
analysis (not 
explicit)
Humulin-Zn vs 
Neulente insulin 
(+/- Actrapid if required)
B1 -Fritsche et al A B C A
(2003) Blinded 
randomisation 
with a schedule 
generated by the 
sponsor 
stratified by 
centre on 1:1:1 
basis
ITT analysis 
(required 1 
dose of study 
medication) 
with 8% drop 
outs
Glimepiride +/- morning 
or bedtime insulin 
glargine or bedtime NPH
B2 -  Roach et al A A C A
(2001) Randomisation 
claimed but not 
described.
ITT analysis 
and full 
follow-up
NPH/regular insulin vs 
NPL/insulin lispro
Groups seem 
comparable
B3 -  Taylor et al
(2000)
A
Randomisation 
stated and cross­
over design. 
Groups seem 
comparable
D
Analysis by 
treatment 
received with 
18% drop outs
C
Twice-daily NPH vs 
once-daily ultralente
A
B4 -  Bastyr et al
(2000)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
D
Analysis by 
treatment 
received with 
16% drop outs
C
Metformin + glyburide 
vs bedtime NPH + 
glyburide vs preprandial 
insulin Lispro + 
glyburide
A
B5 -  Chiasson et al
(1994)
EXCLUDED-NO 
INSULIN 
CONTAINING 
ARM
B
Randomisation 
claimed but not 
described. 
Different 
durations of 
diabetes among 
groups.
D
Analysis by 
treatment 
received with 
90% included 
in efficacy 
analysis but 
25% drop outs
A
Addition of acarbose or 
matched placebo to 
either dietary, insulin, 
metformin or 
sulphonylurea therapy
A
B6 -  Yki-Jarvinen
et al (1992)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
B
?ITT analysis 
with 3% drop 
outs
C
OHAs + evening-NPH 
vs OHA + moming-NPH 
vs OHAs alone vs 
Mixtard 30/70 bd vs 
evening-NPH + pre­
prandial regular insulin
A
B7 -  Wolffenbuttel
et al (1996)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
B
ITT analysis 
with 7% drop 
outs
C
Mixtard 30/70 bd vs 
bedtime-NPH + 
glibenclamide vs 
moming-NPH + 
glibenclamide.
A
B8 -  Yki-Jarvinen
et al (1999)
A
Randomisation 
into four groups 
using 
minimisation of 
differences for 
specified 
variables
C
Analysis by 
treatment 
received with 
8% drop outs
C
Bedtime NPH plus:
i) breakfast NPH or
ii) Glyburide plus 
placebo-metformin or
iii) Metformin plus 
placebo-glyburide or
iv) metformin plus 
glyburide
A
B9 -  Bastyr et al
(1999)
A
Randomisation
B
ITT analysis
C
Sulphonylurea plus
A
claimed but not 
described. 
Groups seem 
comparable
with 6% drop 
outs
preprandial insulin lispro 
vs Sulphonylurea plus 
bedtime-NPH vs 
bedtime-NPH plus 
preprandial insulin lispro
BIO -  UKPDS 34
(1998)
A
Random 
assignment with 
centrally 
produced, 
computer 
generated 
allocations in 
sealed opaque 
envelopes.
B
ITT analysis 
with 4% drop 
outs
C
Unblinded comparison 
of multiple different 
therapies
A
B ll -  Roach et al
(1999)
A
Randomisation 
stated and cross­
over design. 
Groups seem 
comparable
A
ITT analysis 
and full 
follow-up
C
Humalog Mix50 pre­
breakfast plus Mix25 
pre-dinner vs human 
insulin 50/50 pre­
breakfast plus 30/70 pre­
dinner
A.
B12 -  Roach, Yue 
and Arora (1999)
A
Randomisation 
stated and cross­
over design. 
Groups seem 
comparable
B
ITT analysis 
with 10% drop 
outs
C
Humalog Mix25 bd vs 
human insulin 30/70 bd
A
B13 -  Riddle et al
(2003)
A
Randomisation 
in the order 
which subjects 
qualified using a 
centralised 
telephone 
system
B
ITT analysis 
with 9% drop 
outs
C
Insulin glargine (clear 
solution) vs human NPH 
(cloudy solution)at 
bedtime
A
B14-UKPDS 57 
(2002)
A
Random 
assignment with 
centrally 
produced, 
computer 
generated 
allocations in 
sealed opaque 
envelopes.
B
ITT analysis 
with 4% drop 
outs
C
Diet vs insulin vs 
sulphonylurea + insulin
A
B15 -  Davies et al
(2005)
A
Randomisation 
claimed but not 
described. 
Groups seem 
comparable
B
ITT (&PP) 
analysis with 
9% drop outs
C
Patient-lead vs clinician- 
lead insulin glargine 
titration algorithm -  
blinding not possible
A
B16 -  Janka et al A B C A
(2005) Random 
assignment 
stratified by 
centre with 
centrally 
produced, 
computer 
generated 
allocations
ITT analysis 
with 2% drop 
outs
Glargine + glimepiride + 
metformin vs Mixtard 
30/70 twice daily
B17-Raskin et al A B C A
(2005) Stratified 
randomisation 
using lowest 
number 
available to each 
site. 
Groups seem 
comparable
ITT analysis 
with 10% drop 
outs
Biasp70/30 twice daily 
+/- OH A vs insulin 
glargine +/- OHAs
B18 -  Malone et al A B C A
(2003) Stratified 
randomisation 
stated, not 
described. 
Groups seem 
comparable
ITT analysis 
with 9% drop 
outs
Mix25 + metformin vs 
glibenclamide + 
metformin
B19-Kilo et al A B C A
(2003) Randomisation 
claimed but not 
described. 
Groups seem 
comparable
ITT analysis 
with 6% drop 
outs
BIAsp30 od + metformin 
vs bedtime NPH + 
metformin vs Mixtard 
30/70 od + metformin
B20 - Christiansen A B A A
et al (2003) Randomisation 
claimed but not 
described. 
Groups seem 
comparable
ITT analysis 
with 3% drop 
outs
BIAsp30 twice daily vs 
NPH twice daily
Quality Appraisal Conclusions
95 articles were identified as eligible for inclusion after title and abstract review. Seven 
of these studies were excluded after quality appraisal of the full publication for the 
reasons as stated in the table above.
After critical review of all eligible studies I have made the following general observations 
and conclusions:
• There are a large number of single centre, small trials with a limited number of 
patients
• Methodology and quality have improved with the passage of time
• Glycaemic targets have become more aggressive over the last few decades and 
this is reflected in study designs. Many of the patients in the older trials would not 
even be eligible for inclusion in more recent trial due to their very poor glycaemic 
control.
• Some of the conclusions of the smaller, older trials are questionable due to 
methodological concerns or significant differences caused by the evolution of 
clinical practice.
• Reductions in HbAlc become increasingly difficult to achieve as the glycaemic 
targets become lower. This poses particular challenges for newer agents in terms 
of demonstrating both a clinically and statistically significant difference to 
existing treatments. Trials evaluating the newer agents are generally appreciably 
larger in order to obtain adequate statistical power to demonstrate small 
differences between treatments
• Large scale trials and those published in well-recognised, peer-reviewed journals 
are of higher quality
• Loss to follow-up and drop-outs increase with the duration of the study and the 
complexity of study visits. Many of the older, smaller studies claim complete 
follow-up/retention of enrolled patients. It seems likely that some investigators 
may simply exclude patients who are lost to follow-up from the discussion and 
final analysis.
• Where studies do not comment on withdrawals or loss to follow-up, it is difficult 
to know if there were any. It is not safe to assume that no comment, means no 
withdrawals even in short-term, small studies
• The majority of the studies are not blinded, most likely due to difficulties inherent 
in requiring patients to undergo placebo subcutaneous injections
• The potential bias introduced by lack of blinding is partially offset by the fact that 
most of the trials have a ‘hard endpoint’ of HbAlc. However the lack of blinding 
may still allow a systematic bias to be introduced by virtue of other changes to the 
patients management that may influence their glycaemic control
• All trials had some form of standardised assessment of glycaemic control, most 
commonly HbAlc and FPG. As newer agents, such as the rapid-acting insulin 
analogues often struggle to demonstrate significant superiority on these traditional 
outcomes, other parameters such as post-prandial glucose or glycaemic excursion 
are increasingly being evaluated and presented
• The method of randomisation is frequently described very poorly. Some studies 
that claim ‘randomisation’ use highly questionable techniques and these are 
sometimes reflected in significantly unbalanced groups at baseline. Conversely, it 
is truly remarkable to see how similar randomised groups are at baseline in the 
large, well randomised studies
• The nature of the final analysis i.e. ITT, per-protocol or treatment received is 
frequently not explicitly stated, especially with older studies. There is no 
consensus in the literature as to what is acceptable to define as ITT analysis. Most 
studies do not include all randomised patients, but rather prefer to base it on all 
randomised patients who receive at least one dose of study drug.
1 NHMRC (2000). How to review the evidence: systematic identification and review 
of scientific literature. National Health and Medical research Council. Biotext, 
Canberra. ISBN 1864960329
Insulin regimens vs O H A s  (n=22)
A total of 22 studies that performed a randomised comparison of insulin vs oral 
hypoglycaemic agents were eligible for final analysis.
UKPDS studies (n=4)
The biggest source of data comparing insulin to OHAs comes from the UK 
Prospective Diabetes Study Group and I have included data from 4 separate UKPDS 
publications (UKPDS 33 (1998), 34 (1998), 49 (1999) and 57 (2002)) as they each 
include different findings of relevance. The most important finding of the UKPDS 
study was that it established the benefits of intensive treatment of type 2 diabetes with 
impressive reductions in microvascular endpoints. Prior to UKPDS, some clinicians 
felt that tight glycaemic control was not important in type 2 diabetes and simply 
focused on avoidance of symptoms of hyperglycaemia. An addition finding of 
importance, presented in UKPDS 49 (2002) is the observation that there is a 
progressive deterioration of diabetes control such that the majority of patients with 
type 2 diabetes will ultimately require multiple therapies.
In terms of glycaemic control in non-obese patients with recently diagnosed type 2 
diabetes, no agent stood out within the different intensive control groups (UKPDS 33 
(1998)). A greater proportion of patients assigned to insulin had achieved a 
FPG<7.8mmol/L after 9 years follow-up, but this did not translate into improved 
HbAlc. Overall, oral agents were associated with less weight gain and a lower rate of 
hypoglycaemia than insulin therapy. On this basis, it would seem reasonable to prefer 
the use of oral agents initially and reserve insulin for patients with inadequate control 
on oral therapy.
In obese type 2 diabetics, UKPDS 34 (1998) data would suggest that metformin 
should be considered the agent of choice for first line drug therapy. It achieved similar 
glycaemic control to the other intensive therapy groups, but achieved a significantly 
greater reduction in ‘any diabetes related endpoint’ and a greater reduction in all­
cause mortality. Metformin was also the only agent to achieve a statistically 
significant reduction in the risk of macrovascular disease (RRR 30% p=0.020). 
Addition of metformin to sulfonylurea was associated with a surprising, significant
92
increase in the risk of diabetes related death. It is very difficult to know how to 
interpret this finding in the context of the favourable findings for metformin when 
used first line. I feel that the finding of increased mortality when metformin is added 
to sulfonylurea may represent extreme play of chance as it is based on relatively low 
number of outcomes. Overall, the data suggests that metformin should be the 
preferred agent of choice for first line use in obese type 2 diabetics.
Studies comparing continued oral therapy to initiation of insulin (n=8)
There were eight eligible studies that compared continuation of oral therapy to 
initiation of insulin therapy.
Six of these studies included patients who had secondary oral failure (Herz M et al 
(2002), Roach P et al (2001), Tovi J. et al (1998), Birkeland K et al (1996), Sotaniemi 
E et al (1990), and Yki-Jarvinen H et al (1992)). Two studies compared insulin to 
sulfonylurea in patients who had failed dietary treatment (Samanta et al. 1987, 
Alvarsson et al. 2003).
Initiation of insulin therapy in the context of secondary oral failure consistently 
improved glycaemic control with a mean decrease in HbAlc of 1.96% (range: -1 to - 
4.9). Factors which influence the degree of improvement in HbAlc may include the 
study duration, the glycaemic targets specified by the study protocol and the degree of 
glycaemic control at the study’s outset. Weight gain is a consistent finding upon 
initiation of insulin therapy with a mean weight gain of 2.75kg (range +0.8 to +6kg). 
Likewise, the rate of hypoglycaemia increases upon initiation of insulin and tighter 
glycaemic control is associated with an increased risk of hypoglycaemia. Overall, 
these data demonstrate clear benefits of initiating insulin in patients with secondary 
oral failure, at a cost of moderate weight gain and increased risk of hypoglycaemia.
The choice of insulin therapy and whether or not to combine with oral therapy will be 
discussed in detail when the relevant studies are reviewed in a later section. It is 
however worth paying particular attention to the study by Yki-Jarvinen (1992), as it 
performed a very useful comparison between five different therapeutic regimens 
commonly used in patients with secondary oral failure. In this study, insulin therapy
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reduced HbAlc by an average of 1.75% after 3 months. Multiple insulin injection 
regimens (Mixtard 30/70 or basal bolus regimen) were no more effective than a 
simpler regimen of NPH once daily in combination with oral agents. The best insulin 
regimen based on best glycaemic control, least weight gain and less 
hyperinsulinaemia was bedtime NPH with continued OHAs.
Another important observation made by Herz M et al (2002) was the fact that 
Humalog Mix25 offered the convenience of post-prandial dosing (<15mins) without 
compromise to glycaemic control when compared to Humalog Mix25 given 
immediately pre-prandially.
Data from Alvarsson M et al (2003) and Roach P et al (2001) also suggest that insulin 
can be inititated without significantly compromising the patients quality of life or 
treatment satisfaction.
Studies comparing addition of a second oral agent to the initiation of insulin 
(n=10)
A total of ten eligible studies were identified which compared the addition of a second 
oral agent to the initiation of insulin in patients with secondary oral failure. The 
addition of a second oral agent consistently improved glycaemic control to a similar 
extent as the initiation of insulin.
Eight of the ten studies evaluated the addition of metformin to sulfonylurea, vs insulin 
alone or in combination with an oral agent (Niazi R. and Muzaffar Z (1998), Calle- 
Pascual A.L. et al (1995), Klein W (1991), Groop L et al (1989), Groop L and Widen 
E (1991), Holman R, Steemson J and Turner R. (1987), Bastyr E et al (2000), Malone 
J et al (2003)).
In these eight studies the addition of metformin reduced HbAlc by an impressive 
mean of 2.35% (range -1.1 to -5). This compared to a remarkable similar mean 
reduction of 2.25% (range -1.5 to -4.1) with insulin based regimens. Patients 
randomised to the addition of metformin lost a mean of 0.4kg (range -1.2kg to 
+0.4kg) whereas patients receiving insulin consistently gained weight, with a mean
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gain of 2.3kg (range +0.8 to +4.1). On the basis of these eight studies, the addition of 
a second oral agent should be preferred to the early initiation of insulin.
One study (Fanghanel et al 1996) evaluated metformin alone vs insulin alone in 
patients with secondary sulfonylurea failure. Both treatments achieved similar 
impressive reductions in HbAlc of approx. 4%, but metformin had other significant 
benefits on weight loss, blood pressure and lipids that may help explain the apparent 
impact of metformin on macrovascular disease observed in UKPDS.
The study by Schwartz et al (2003) evaluated triple oral therapy (secretagogue, 
metformin + glitazone) vs Novolin 70/30 bd + metformin in patients with inadequate 
glycaemic control on two oral agents. In this study both treatments achieved a similar 
improvement in HbAlc of approx 2% and similar weight gain. Triple oral therapy 
was more expensive than initiation of insulin, but either regimen would seem a 
reasonable option based on these results.
95
Comparison of different insulin regimens (n=31)
A total of 31 of the eligible studies evaluated different insulin regimens, either alone 
or where randomised groups received the same oral therapy. The number of different 
regimens compared in these studies highlights the large number of different options 
available to patients and clinicians. Many of the studies demonstrate similar 
glycaemic control and so other therapy related issues such as weight gain, frequency 
of hypoglycaemia or complexity of regimen assume increased importance.
To aid in the interpretation of these studies I have grouped them based on trials which 
make similar randomised comparisons.
Comparison of insulin glargine and NPH (n=6)
Six studies were identified evaluating insulin glargine in type 2 diabetes.
Five of these compared insulin glargine to NPH, which is currently the most common 
used basal insulin (HOE 901/2004 Study Investigators Group (2003), Rosenstock et al
(2001), Yki-Jarvinen H et al (2000), The HOE 901/3002 Study Group, Fritsche A et 
al (2003), and Riddle M et al (2003)).
In these five studies, both glargine and NPH lead to similar significant improvements 
in glycaemic control. HbAlc was reduced by a mean of 1.01% on insulin glargine 
(range -0.41 to 1.65%). HbAlc was reduced by a mean of 0.92% on NPH (range -0.59 
to -1.59%).
The study by Fritsche et al (2003) found that morning insulin glargine provided better 
glycaemic control than either bedtime glargine or bedtime NPH, but it is difficult to 
know how to interpret this isolated finding.
Differences in reporting and classification of hypoglycaemia between trials make it 
difficult to pool the data, but there is a consistent finding of fewer nocturnal 
hypoglycaemic episodes on insulin glargine compared to NPH. It is possible that in 
‘real-world’ clinical practice the higher rate of hypoglycaemia with NPH may lead to
inferior glycaemic control as patients may end up reducing there insulin dose due to 
fear of recurrent hypoglycaemia, however this remains unproven.
One study Davies et al. (2005) compared a patient lead glargine titration algorithm to 
a physician lead titration algorithm. It found that the patient-lead algorithm achieved 
marginally better glycaemic control at the expense of a small increase in the rate of 
hypoglycaemia.
Based on its superior pharmacokinetic profile and reduced risk of nocturnal 
hypoglycaemia, it would seem reasonable to prefer insulin glargine to NPH as the 
basal insulin of choice, particularly in patients who have problems with nocturnal 
hypoglycaemia on NPH.
Comparisons between different basal insulins (not including NPH vs glargine) 
(n=4)
Four other studies primarily addressed the choice between the other (non-glargine) 
basal insulins (Holman et al (1987), Tindall et al (1988), Stehouwer et al (2003) and 
Taylor et al (2000)).
The small cross-over study by Holman et al (1987) suggested that basal insulin 
(Ultralente), alone or in combination with a sulfonylurea, were preferable to the 
addition of metformin in patients with inadequate glycaemic control on maximal dose 
sulfonylurea.
Tindall et al (1988) demonstrated improved glycaemic control with the use of a basal 
insulin in patients with secondary oral failure. They found Neulente insulin to be 
preferable to Humulin-Zn due to the high rate of nocturnal hypoglycaemia with 
Humilin-Zn.
Stehouwer et al (2003) demonstrated that twice daily insulin (NPH or Mixtard) is 
superior to bedtime NPH + glimepiride in obese patients with secondary oral failure.
The study by Taylor et al (2000) also supports the use of NPH twice daily, as it 
achieved superior glycaemic control to Ultralente once daily, with significantly 
greater reductions in HbAlc and fewer hypos.
Comparison of synthetic vs human combinations of intermediate and short 
acting insulin twice daily (n=7)
Seven studies were identified which compared different twice daily regimens 
consisting of a mixture of intermediate and short-acting insulin, whether as pre-mixes 
or administered separately (Herz M et al (2002), Herz M et al (2003), Boehm B et al
(2002), Ross S et al (2001), Roach P et al (1999), Roach P et al (2001), Roach P, Yue 
L and Arora V (1999)).
These studies have all been published since 1999 as part of the development program 
for the newer rapid-acting insulin analogues insulin lispro (n=6) and insulin aspart 
(n=l). They have compared these newer analogues to human insulin. It is prudent to 
consider the sponsorship of the studies and affiliation of the authors when considering 
the validity of the conclusions presented in the publications. I feel that the authors 
tend towards overstating the value of the newer agents.
None of the studies demonstrated the newer insulin analogues to achieve superior 
glycaemic control as assessed by HbAlc. However, all seven studies found the new 
rapid acting analogues achieved superior post-prandial glucose control, with smaller 
post-prandial glycaemic excursions. This occurred in all studies, both when regular 
insulin was administered 30-45mins pre-meal or when it was administered 
immediately pre-meal. It is difficult to be certain of the clinical significance of this 
improved post-prandial control.
The rapid action of the insulin analogues enables greater flexibility in dosing as they 
may be administered immediately pre-meal. Another potential advantage of the 
insulin analogue based regimens is a trend towards fewer hypoglycaemic episodes, 
though this was not a consistent finding in the trials.
Overall, the insulin analogues can be considered to provide greater flexibility and 
improved post-prandial glycaemic control. These small benefits may justify a
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preference for these agents over human insulin equivalents; however their use may be 
restricted in many markets due to their higher cost.
Comparison between different basal bolus regimens (n=2)
Only two studies were identified which directly compared different basal bolus (QID) 
regimens (Sargin et al (2003) and Anderson et al (1997)).
The study by Sargin et al (2003) provided good data to support the rationale of a basal 
bolus regimen in type 2 diabetics who are inadequately controlled on twice daily 
insulin therapy. In this study, both basal bolus regimens achieved impressive 
reductions in HbAlc. The lispro based regimen reduced the mean HbAlc by 2.3%, 
whereas the regular insulin based regimen reduced it by a 1.5%. It is difficult to know 
how much of the superior glycaemic control observed with lispro can be attributed to 
lispro alone, as this regimen included twice daily NPH, whereas the regular insulin 
based regimen received once daily NPH; the rationale for the extra dose of NPH was 
that preprandial hyperglycaemia may occur with insulin lispro due to the short 
duration of action.
The second study by Anderson et al (1997) also compared lispro to regular human 
insulin in a basal bolus regimen. As in the studies of twice daily regimens, lispro 
improved post-prandial glycaemic control but this did not translate into a superior 
glycaemic control as assessed by HbAlc.
Overall, in these two studies, basal bolus regimens have been demonstrated to 
improve glycaemic control in type 2 diabetics patients who are inadequately 
controlled on their current insulin regimen. Insulin lispro affords the convenience of 
being able to dose immediately pre-meal and improves post-prandial glycaemic 
control. On this basis it should be preferred to regular human insulin as the prandial 
insulin of choice
Comparison of basal bolus regimen to insulin pump therapy (n=2)
Only two studies comparing continuous insulin pump therapy to a basal bolus insulin 
regimen in type 2 diabetes were identified (Saudek et al (1996) and Raskin P et al
(2003)).
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HbAlc improved by a similar amount with either therapy. The study of the MiniMed 
implantable pump by Saudek et al (1996) revealed potential advantages of fewer 
hypoglycaemic episodes and less weight gain. However, the need for surgical 
implantation under general anaesthesia and potential problems with the pump leading 
to insulin under-delivery suggest that this treatment is probably not preferable to a 
basal bolus subcutaneous regimen.
Insulin pump therapy may be considered in patients who have inadequate control on a 
basal bolus regimen or those with problems with recurrent hypoglycaemia.
Comparison of intensive vs less intensive insulin therapy (n=2)
Two of the eligible studies undertook a randomised comparison between intensive 
insulin therapy vs ‘standard’ or ‘conventional’ insulin therapy (Abraira et al (1998) 
and Ohkubo et al (1995)).
The study by Abraira et al (1998) utilized a step wise escalation of therapy targeting 
aggressive control with compelling results. Bedtime basal insulin reduced HbAlc by 
1.4%. When this failed, the addition of gliclazide achieved a further 0.5% reduction. 
Conversion to a twice daily insulin regimen only managed to maintain current 
HbAlc. And finally patients who progressed to require a basal bolus QID regimen 
achieved a further 0.6% reduction. Overall the intensive therapy group maintained an 
HbAlc approx 2% lower than the standard therapy group for over two years of 
follow-up. The downside of intensive therapy was significant increases in 
hypoglycaemic episodes, with each 0.5% fall in HbAlc leading to a doubling in the 
rate of reported hypos.
The second study by Ohkubo et al (1995) provided further compelling evidence as to 
the benefits of tight glycaemic control with insulin. A regimen consisting of multiple 
insulin injections achieved a 2% reduction in HbAlc (down to 7%). After six years of 
follow-up this tight control lead to significant reductions in the rate of development or 
progression of retinopathy or nephropathy.
Tight glycaemic control with insulin therapy is achievable and advantageous.
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Insulin therapy in combination with metformin (n=13)
Comparisons of the addition of metformin to insulin vs insulin alone (n=8)
There were eight eligible studies that evaluated the addition of metformin to insulin 
therapy (Wulffele MG et al (2002), Strowig S et al (2002), Hermann L et al (2001), 
Ponssen H et al (2000), Aviles-Santa L et al (1999), Relimpio F et al (1998), 
Robinson A et al (1998), Giugliano D et al (1993)).
Most of these studies recruited patients who had inadequate glycaemic control on 
their current insulin containing regimen. As such, these patients have slightly more 
advanced diabetes than in trials evaluating the addition of sulfonylurea, where patients 
are more commonly insulin naive. Despite the relatively advanced diabetes, the 
addition of metformin leads to consistent benefits in glycaemic control, with 
additional advantages of less weight gain and lower daily insulin requirements.
Based on the pooled data from eight studies, the addition of metformin lead to a mean 
decrease in HbAlc of 1.15% (range 0 to -2.05%) over and above that which was 
achieved in the control group. The metformin group also gained a mean of 1.8kg less 
weight than the control group. The only down side to the addition of metformin was a 
significant increase in gastrointestinal complaints which lead to treatment 
discontinuation in several patients.
Overall, these studies support the addition of metformin in insulin requiring type 2 
diabetics. The lack of an association with weight gain is an important therapeutic 
benefit of metformin, especially in type 2 diabetes where weight reduction is 
generally recommended. The avoidance of weight gain may partially explain the 
apparent benefits in the risk of macrovascular disease observed in obese patients in 
UKPDS who were assigned to metformin.
Miscellaneous comparisons of insulin + metformin and other regimens (n=5)
There were five other eligible studies evaluating the use of metformin in combination 
with insulin in various ways (Schwartz et al (2003), Yki-Jarvinen et al (1999), Janka 
et al (2005), Malone et al (2003) and Kilo et al (2003)).
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The study by Schwartz et al (2003) compared triple oral therapy to a combination of 
Novolin70/30 bd + metformin in 188 patients with inadequate glycaemic control on 
two oral agents. Both options achieved similar improvements in HbAlc of just over 
2% and weight gain was also similar. The authors argue that the insulin regimen 
should be preferred due its significantly lower cost. I suggest that either regimen 
could be considered and that triple oral therapy may be useful in patients who are 
eager to avoid insulin injections.
Yki-Jarvinen et al (1999) conducted a very useful head-to-head comparison of the 
addition of metformin or glyburide to bedtime NPH in 96 patients with secondary 
sulfonylurea failure. Use of metformin in combination wth NPH was a clear winner 
based on the greatest reduction in HbAlc and the lack of weight gain. Interestingly, 
the group who received both metformin + glyburide + NPH did not derive additional 
benefit in terms of glycaemic control and lost the weight benefits seen with metformin 
alone. Four patients receiving metformin dropped out due to gastrointestinal side 
effects.
The study by Janka et al (2005) demonstrated insulin glargine + metformin + 
glimepiride to be superior to Mixtard 30/70 bd in 364 patients with secondary oral 
failure. The glargine based regimen achieved slightly superior glycaemic control and 
fewer hypoglycaemic episodes.
Malone et al (2003) suggested that the use of Mix25bd + metformin may be 
preferable to the combination of glibenclamide + metformin in patients with 
inadequate glycaemic control on a single oral agent. However the overall glycaemic 
control was similar between the groups, so I feel in most situations the addition of a 
second oral agent is preferable to the early initiation of insulin, as outlined in previous 
sections.
Kilo et al (2003) demonstrated comparable improvements in glycaemic control with 
three different metformin based regimens. The use of pre-dinner biphasic insulin was 
no more effective than bedtime NPH.
Summary of evidence supporting the use of insulin in combination with 
metformin
There is a significant base of evidence supporting the addition of metformin to 
patients with insulin requiring type 2 diabetes. Perhaps the most difficult question 
relates to the choice between continuing metformin vs a sulfonylurea (or both). 
Metformin achieves similar improvements in HbAlc to the addition of sulfonylureas. 
Metformin has additional benefits on other metabolic parameters, most notably 
weight gain, but perhaps also blood pressure and lipids. In view of these potential 
benefits, I recommend metformin be preferred in obese type 2 diabetics with 
secondary oral failure. In non-obese type 2 diabetics, it may be reasonable to 
recommend a sulfonylurea in view of their superior gastrointestinal tolerability. An 
alternate approach may be to have a trial of metformin first and switch to sulfonylurea 
only if the metformin is poorly tolerated.
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Insulin use in combination with sulfonylurea (n=28)
The use of sulfonylureas in combination with insulin has been evaluated in the largest 
number of randomized clinical trials (n=28) of all the various oral agents. This 
combination is very commonly utilized in clinical practice and is particularly valuable 
in patients who prefer to avoid a regimen consisting of multiple daily injections of 
insulin.
Comparisons of the addition of a sulfonylurea to insulin vs addition of 
placebo/control to insulin (n=14)
There were fourteen eligible studies that compared the addition of a sulfonylurea to 
the addition of placebo or nothing (Riddle M et al (1989), Ravnik-Oblak and Mrevlje 
(1995), Riddle M et al (1992), Lewitt et al (1989), Casner P (1988), Lins P. et al 
(1988), Mauerhoff T, Ketelslegers J and Lambert A (1986), Falko J and Osei K 
(1985), Groop L et al (1985), Groop L, Harno K and Tolppanen E (1984), Riddle M 
and Schneider J (1998), Feinglos M et al (1998), Quatraro A et al (1986) and Abraira 
C et al (1998)).
The most commonly used sulfonylurea in these studies was glibenclamide (glyburide) 
(n=ll). No studies conducted a head to head comparison between different 
sulfonylureas.
The design of these studies varied considerably making it difficult to pool or compare 
data from the different studies. Most of these studies only included 20-30 patients, 
with the largest study randomizing just 145 patients (Riddle M and Schneider J 
(1998)).
Many of the studies evaluated patients with secondary oral failure and thus even the 
control groups had significant falls in HbAlc upon the introduction of insulin. For this 
reason, it is most relevant to compare the difference in HbAlc and weight gain 
between groups, rather than the change from baseline alone. The benefits of 
sulfonylureas are also likely to be diminished somewhat in patients with secondary 
oral failure due to grossly impaired islet cell function. Some studies propose that 
fasting C-peptide levels may be used to help predict which patients will benefit from 
continuation/addition of sulfonylureas.
Overall in the fourteen eligible studies, the mean reduction in HbAlc attributable to 
the addition of sulfonylurea was -1.41% (range -2.9 to +0.3). The addition of 
sulfonylurea therapy (or continuing it when initiating insulin) lead to an increased risk 
of hypoglycaemia and to a mean weight gain of 0.94kg (range 0 to 2.5kg). The 
majority of the studies also demonstrated benefits with respect to reduction in the 
daily insulin requirements, though this is not consistently reported.
Based on these fourteen studies, there is adequate evidence to support the addition of 
or continuation of a sulfonylurea to insulin in type 2 diabetes. There is insufficient 
evidence to recommend the use of one sulfonylurea over the other. In many 
instances, patients will already be taking a sulfonylurea when they come to need 
insulin therapy, it would seem reasonable to continue their current sulfonylurea in this 
setting due to its established tolerability. Glibenclamide is the most widely studies 
agent and some clinicians may express a preference for this agent on this basis alone.
Comparison of different insulin regimens in combination with sulfonylurea 
(n=10)
There were ten eligible studies that compared the combination of insulin and 
sulfonylurea to alternate insulin regimens, either alone or in combination with the 
same sulfonylurea. (Lanstedt-Hallin L et al (1995), Stehouwer et al (2003), Fritsche 
A et al (2003), Bastyr E et al (2000), Yki-Jarvinen H et al (1992), Wolffenbuttel B et 
al (1996), Bastyr E et al (1999), Janka H et al (2005), Clauson P et al (1996) and 
Chow C et al (1995)).
Several of these studies make an important contribution to our current evidence base 
as they compare the regimens that clinicians and patients must chose between in the 
context of secondary oral failure. Several of these studies assume additional 
importance as they have randomised relatively large numbers of patients. (Stehouwer 
et al (2003) (n=261), Fritsche A et al (2003) (n=695), Bastyr E et al (2000) (n=131), 
Yki-Jarvinen H et al (1992) (n=149), Bastyr E et al (1999) (n=423), and Janka H et al 
(2005) (n=364))
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Due to the number of different regimens compared, it is not possible to conduct a 
pooled analysis. Instead, I will give a brief overview of the key conclusions that may 
be drawn from each of these studies.
Studies favouring multiple insulin injections:
Stehouwer et al (2003) found that both Mixtard 30/70 bd and NPH bd achieved 
superior glycaemic control to bedtime NPH with glimepiride in their study of 261 
obese patients with secondary oral failure. The tighter control with the twice-daily 
regimens came at the expense of a small increase in weight gain and increased rate of 
hypoglycaemia.
Bastyr et al (2000) undertook an interesting comparison between insulin lispro tds + 
glyburide, vs metformin + glyburide vs bedtime NPH + glyburide. Lispro had the 
greatest impact on overall metabolic control, but also the most weight gain and 
highest rate of hypoglycaemia. The metformin group enjoyed freedom from weight 
gain. NPH achieved the lowest FPG. This study highlights some of the different 
merits of each treatment and the challenges faced by clinicians and patients in 
selecting the best regimen for their circumstance.
Wolffenbuttel et al (1996) compared Mixtard bd to NPH + glibenclamide. There was 
a trend towards a greater reduction in HbAlc on Mixtard bd (-3.0% vs -2.5%). 
Continuing glibenclamide reduced daily insulin requirements. Weight gain and rate of 
hypoglycaemia was similar between groups. On balance, it would seem reasonable to 
offer either regimen to patients based on this trial.
Bastyr et al (1999) compared a QID lispro based regimen to tds lispro + sulfonylurea 
and NPH + sulfonylurea in 423 patients with secondary oral failure. The lispro 
regimens achieved marginally superior glycaemic control at the expense of more 
hypoglycaemia and multiple injections per day. The justification of lispro use as 
initial insulin therapy is fairly weak.
Studies favouring single basal insulin dose:
Lanstdedt-Hallin et al (1995) found tds pre-prandial insulin + glibenclamide to be 
fairly comparable to bedtime NPH + glibenclamide overall, with both regimens
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reducing HbAlc by around 2%. Postprandial control was superior on the tds regimen, 
while FPG was superior on NPH.
The study by Clauson et al (1996) found bedtime NPH + glimepiride to be preferable 
to a QID insulin regimen, as they achieved comparable glycaemic control (HbAlc -  
2.5%), but the QID regimen lead to significantly more weight gain.
Fritsche et al (2003) conducted a large study in 695 patients with secondary oral 
failure. They demonstrated that insulin glargine + glimepiride was preferable to NPH 
+ glimepiride, as it achieved marginally better glycaemic control with fewer nocturnal 
hypoglycaemia episodes.
Yki-Jarvinen et al (1992) conducted a very useful comparison of five different 
regimens commonly used in the context of secondary oral failure. They compared 
NPH + OHAs, Mixtard bd, a QID regimen and continued OHAs alone. Mean HbAlc 
improved by a similar amount on all the insulin containing regimens (mean -1.75%). 
On balance of glycaemic control, weight gain, risk of hypos and simplicity of 
regimen, this study would support a preference for bedtime NPH in combination with 
oral agents. Patients may require multiple injections as glycaemic control deteriorates.
The study by Janka et al (2005) compared insulin glargine + glimepiride + metformin 
to Mixtard bd in 364 patients with secondary oral failure. The glargine based regimen 
achieved superior glycaemic control with less hypoglycaemia and should be preferred 
on this basis.
Chow et al (1995) also provide date supporting use of oral agents in combination with 
insulin. Bedtime NPH + OHAs achieved comparable glycaemic control to twice daily 
insulin alone, with significantly less weight gain.
Comparisons of insulin + sulfonylurea to orals alone (n=2)
In addition to the studies which compared oral agents to various insulin regimens 
previously discussed, there were also 2 studies identified which compared the 
combination of insulin + sulfonylurea to the combination of metformin + 
sulfonylurea.
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The study by Niazi and Muzaffer (1998) adds very little to the evidence base due to 
the fact that 50% of patients randomized to insulin discontinued it. The authors report 
that Pakistanis have beliefs against the use of daily injections, which limit its use in 
that cultural setting.
The study by Klein (1991) also has some methodological concerns, as 30% of 
randomized patients were excluded from the final analysis. Nonetheless, impressive 
HbAlc reductions of around 4% were achieved on both regimens.
These two studies add very little to the balance of evidence but are consistent with my 
previously recommended preference for combination oral therapy prior to insulin 
initiation in most settings.
Comparisons of insulin + sulfonylurea to the addition of an alternate oral agent 
(n=2)
Yki-Jarvinen (1999) undertook a very useful comparison between four simple basal 
insulin based regimens commonly used in clinical practice when oral agents have 
failed to achieve adequate glycaemic control. Bedtime NPH + metformin, vs bedtime 
NPH + glyburide, vs bedtime NPH + metformin + glyburide, vs twice daily NPH. 
After 12 months follow-up all four regimens achieved significant improvements in 
HbAlc of around 2%. The combination of metformin with bedtime NPH emerged as 
a fairly convincing winner, due to a combination of the greatest improvement in 
HbAlc (-2.5%), the least weight gain (approx 3kg less than other regimens) and the 
lowest rate of hypoglycaemia. This trial provides fairly compelling evidence to 
support a preference for continuation of metformin, over sulfonylureas when basal 
insulin is initiated in type 2 diabetes. The major limiting factor for metformin use in 
this setting will be gastrointestinal tolerability.
The small study by Guvener and Gedik (1999) compared the addition of sulfonylurea 
to the addition of acarbose. Both regimens achieved similar improvements in HbAlc 
of just over 1%. The acarbose group gained less weight and required less insulin. The 
authors conclude that acarbose seems preferable to gliclazide for use in combination 
with insulin. However, I don’t feel this study provides adequate evidence to justify
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such a preference, as the balance of evidence suggests that acarbose is less effective in 
improving glycaemic control and has significant gastrointestinal side effects that limit 
its use (see subsequent chapter on the use of acarbose with insulin)
Summary of evidence supporting the use of insulin in combination with 
sulfonylurea
There is a large base of evidence from over 3,000 patients in randomised clinical trials 
supporting both the continuation of and the addition of sulfonylureas to patients with 
type 2 diabetes who require insulin. Most of these trials have been conducted in 
patients with secondary oral failure -  this stems from the established preference to 
utilize combinations of oral agents prior to initiating insulin (which is supported by 
UKPDS).
The addition or continuation of sulfonylurea will improve glycaemic control, with 
additional reductions of HbAlc of over 1% generally being observed where it is 
combined with a simple regimen of once daily basal insulin. In this context it achieves 
fairly comparable glycaemic control to more intensive regimens consisting of multiple 
daily injections of insulin alone (Yki-Jarvinen H et al (1992)). The advantages of 
commencing with a regimen of once daily long-acting insulin + sulfonylurea 
compared to a multiple daily insulin regimen include less weight gain, lower daily 
insulin requirements, fewer hypoglycaemia episodes and greater simplicity for the 
patient.
With the passage of time many patients will progress to require a more intensive 
insulin regimen at which time continuation of the oral agents is of limited value.
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Insulin use in combination with glitazones (n=5)
Five studies evaluating the value of the addition of a glitazone to insulin therapy were 
eligible for inclusion in the review (Buse J. et al (1998), Schwartz S et al (1998), Raskin 
et al (2001), Rosenstock J et al (2002) and Strowig S et al (2002)).
Four of the five studies randomised diabetic patients with inadequate glycaemic 
control on insulin alone, to receive placebo, or either a high or low-dose glitazone 
(Buse J. et al (1998), Schwartz S et al (1998), Raskin et al (2001), Rosenstock J et al
(2002). In all four studies there was clear evidence of a dose response with respect to 
glycaemic control and adverse effects. One study by Strowig S et al (2002) compared 
the addition of placebo, troglitazone or metformin to insulin, in patients with 
inadequate glycaemic control on insulin alone.
Based on the pooled data, the addition of high dose glitazone therapy (troglitazone 
600mg, rosiglitazone 8mg or pioglitazone 30mg) lead to a mean reduction in HbAlc 
of 1.1% (range 0 to -2.1%). Daily insulin requirements were also consistently reduced 
in all studies. Mean weight gain across the studies was 3.4kg (range 0 to +5.3kg).
The addition of low dose glitazone therapy (troglitazone 200mg, rosiglitazone 4mg, 
pioglitazone 15mg) produced consistent, smaller improvements in glycaemic control 
than the higher doses. The mean reduction in HbAlc was 0.6% (range 0 to -0.99%). 
Mean weight gain on the lower dose was 2.05kg (range 0 to +4kg). Daily insulin 
requirements were also consistently reduced.
The addition of glitazones also increased the risk of hypoglycaemia and lead to 
reports of oedema in approx 15% of patients. Fluid retention is likely to be a key 
component of the weight gain observed on glitazones and has lead to these agents 
being contraindicated in patients with cardiac failure.
The study by Strowig S et al (2002) demonstrated slightly superior improvements in 
HbAlc with troglitazone compared to metformin. However, this came at the expense 
of more weight gain and increased risk of hypoglycaemia.
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Overall, the addition of glitazones leads to significant improvements in glycaemic 
control and enables insulin doses to be reduced. It does so at a cost of extra 
hypoglycaemic episodes, fluid retention and weight gain.
The addition of a glitazone to insulin therapy should therefore be considered as an 
alternative to the combination of metformin with insulin, or sulfonylurea. However, 
currently both sulfonylureas and metformin have a more extensive evidence base and 
are appreciably cheaper than glitazones, making them the preferred option for most 
patients.
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Insulin use in combination with acarbose (n=6)
Six studies eligible for final analysis evaluated the use of acarbose in combination 
with insulin (Standle et al (1999), Guvener and Gedik (1999), Coniff R et al (1995), 
Hwu et al (2003), Kelley D et al (1998), Chiasson JL et al (1994))
Four of these studies directly compared the addition of acarbose to the addition of 
placebo (Coniff R et al (1995), Hwu et al (2003), Kelley D et al (1998), Chiasson JL 
et al (1994)). These studies demonstrated that the addition of acarbose leads to a 
consistent small reduction in HbAlc (mean -0.45% range 0 to -0.7%). The improved 
HbAlc was largely driven by improved post-prandial glycaemic control. The addition 
of acarbose also leads to small decreases in daily insulin requirements. Adverse 
gastrointestinal effects, particularly flatulence, abdominal cramps and diarrhea were 
common with acarbose and significantly limit the role of acarbose.
One study by Guvener and Gedik (1999) compared the combination of insulin + 
acarbose, with the combination of insulin + gliclazide. Both combinations achieved 
similar improvements in HbAlc of just over 1%, but acarbose had tolerability 
problems with flatulence and bloating.
Standle et al (1999) evaluated the addition of acarbose or placebo to a regimen of 
insulin + glibenclamide. Both arms achieved a significant 2.4% reduction in HbAlc, 
which was largely attributable to the modified insulin regimen. The only important 
benefit of the addition of acarbose was a reduction in insulin requirements of 7u/day. 
This occurred at the expense of a significant increase in gastrointestinal side effects 
and does not warrant use of acarbose in this setting.
Overall, the combination of other oral agents with insulin should be preferred to the 
combination of acarbose and insulin, due to superior tolerability and greater 
improvements in glycaemic control. Acarbose may have a role in patients where post­
prandial hyperglycaemia is problematic or as a third line oral hypoglycaemic agent.
General comments
The target HbAlc for patients with type 2 diabetes has progressively fallen over the 
past few decades as the benefits of tight glycaemic control have been convincingly 
demonstrated. The lower targets currently being recommended in clinical practice are 
apparent both in clinical trial designs and in the level of glycaemic control apparent in 
clinical trial patients at baseline. And yet even in a clinical trial setting many patients 
fail to achieve the targets. Nonetheless, as glycaemic control improves and the 
therapeutic armamentarium grows larger, it is becoming increasingly difficult for new 
agents to demonstrate that they provide an important therapeutic advance.
Reporting of hypoglycaemia has become more important as target HbAlc has fallen. 
In general, tighter glycaemic control increases the risk of hypoglycaemia. Many 
studies included in my analysis, reported hypoglycaemia rates inadequately or not at 
all. The quality and consistency of reporting has improved in recent years, making 
comparison between different trial results somewhat easier. There is clearly a need for 
patients and their relatives to be educated as to the symptoms of hypoglycaemia and 
recognize the need to intervene early.
There is currently no consensus among physicians and experts about the proper 
schedule for the administration of insulin in patients with type 2 diabetes. The large 
number of regimens available serves to increase uncertainty and may be somewhat 
overwhelming for clinicians. In the absence of specific clear recommendations, it is 
useful to consider the following general guidance as to the use of insulin in type 2 
diabetes:
• Develop expertise in a limited number of regimens (to allow for patient 
preferences, lifestyle, etc.) and use them consistently.
• Insulin resistance creates the potential need for large doses of insulin. In the 
usual patient with type 2 diabetes, the dose is in the range of 0.6 to 1.0 
units/leg per 24 hours
Insulin therapy in Type 2 diabetes
Conclusions and Recommendations
• Once a regimen has been chosen, increase doses incrementally until glycaemic 
targets are achieved. It is preferable to avoid frequent changes to the insulin 
regimen, as this will tend to delay the achievement of goals and may confuse, 
frustrate and demoralize the patient.
• Keep it simple. In many patients with type 2 diabetes, a single dose of insulin 
per day is sufficient. The need for multiple doses of insulin becomes apparent 
if control remains suboptimal on high doses of basal insulin or if control is 
only acceptable at certain times of the day.
Evidence-based treatment recommendations
In September 2002, the National Institute for Clinical Excellence concluded 
(McIntosh A et al 2001):
" Insulin therapy should be offered to people with diabetes with 
inadequate blood glucose control on optimised oral glucose-lowering 
drugs. ”
In addition they recommended that:
“Local experience, patient preference and relative costs should inform 
the choice o f insulin type and regimen as there is little research 
evidence in this area ”
Based on my review of the evidence, both of these statements remain partially true. 
However, I believe there is now adequate evidence to support the benefits of specific 
agents and of a stepwise approach to the introduction of insulin as outlined below. 
Like many therapeutic areas, the ‘best’ treatment will depend on an assessment of a 
number on patient factors and perhaps most importantly on patient preference. In 
many ways we are fortunate to be in a position of having multiple treatment options, 
which enables patients to choose which suits their needs the best.
-114-
P r o p o s e d  in s u l in  t r e a t m e n t  a l g o r i t h m
Initial diagnosis: 
Diet and Exercise 
(see note 1)
:
HbAlc>7.0%
Oral hypoglycaemic 
therapy 
(see note 2)
x
Metformin 
(if obese)
/■fa i ; i s i s f i
Sulfonylurea 
(if non-obese)
HbA lc>7.0% HbA 107.0%
Metformin.+/•
Sulfonylurea 
(see note 3)
HbAlO7.0%
X
Add Glitazone 
(see note 4)
Add basal insulin 
once daily 
(see note 5)
ill
HbA 107.0%
1
Add prandial insulin 
QID regime 
(see note 6)
Change to mixture 
of basal + prandial 
insulin twice daily 
(see note 7)
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Treatment algorithm explanatory notes 
Note 1:
Patients with type 2 diabetes should be treated in a step-wise manner. Initially 
attempts should be made to normalise glycaemia using diet and exercise, with weight 
loss if overweight. Considerable improvements in glycaemia can be achieved through 
a combination of diet and exercise.
Note 2:
When patients fail to achieve adequate glycaemic control on dietary therapy alone, 
initiation of an oral hypoglycaemic agent is appropriate. The most compelling data 
supporting first line use of oral agents comes from UKPDS where patients assigned to 
intensive insulin from the outset experienced comparable glycaemic control to those 
taking oral agents, but suffered greater weight gain and more frequent hypoglycaemia. 
Consideration of which oral agent to use first is beyond the scope of this dissertation, 
but most clinicians recommend metformin in obese patients, due to a lack of weight 
gain and potential cardiovascular benefits. Non-obese patients will often commence a 
sulfonylurea due to superior tolerability and comparable glycaemic control.
Note 3:
If glycaemic control deteriorates further on monotherapy, it is appropriate to add a 
second agent (sulfonylurea or metformin). Some clinicians argue that in order to reach 
the latest aggressive HbAlc targets of 6.5% or 7% it may be appropriate to add 
insulin earlier, rather than a second oral agent. This would seem a reasonable 
approach in patients with very poor glycaemic control (HbAlc>9.0%), as usually the 
addition of a second oral agent will only reduce HbAlc by approximately 1-2%. 
However, most patients express a preference to avoid injections if possible and so I 
would advocate a trial of additional oral therapy in combination with reiterating the 
importance of adhering to diet and exercise recommendations. Some patients may be 
more compliant with lifestyle recommendations, if they are motivated to avoid insulin 
injections. Patients who do not tolerate metformin due to gastrointestinal side effects 
may also be considered as candidates for a glitazone in combination with 
sulfonylurea, prior to initiating insulin.
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Patients with secondary oral failure on maximal doses of a combination of metformin 
+/- sulfonylurea have several different options. The addition of a third oral agent is a 
reasonable choice, particularly in those patients who express a preference to avoid 
insulin injections. The glitazones have been shown to improve glycaemic control in 
this setting, though the total cost of triple oral therapy may be higher than that of 
initiating insulin therapy.
Acarbose may be considered an option by some patients and clinicians, but it has only 
a very limited role in therapy due to its poor gastrointestinal tolerability and relatively 
small impact on glycaemic control. It has a role to play in patients whose major 
problem is post-prandial glycaemic control, or in patients with contraindications to the 
alternative oral agents.
Patients who chose to add a glitazone to their dual oral therapy will ultimately require 
addition of insulin as their glycaemic control deteriorates. Glitazones are not licensed 
for use in combination with insulins in all markets, but they do have evidence to 
support their role in this capacity. Similar to sulfonylureas and metformin, the use of a 
glitazone in combination with insulin has been shown to further improve glycaemic 
control and to reduce insulin requirements. They do so at a cost of increased weight 
gain (largely due to fluid retention) and remain relatively expensive agents. I feel the 
currently available data favours the use of metformin in combination with insulin, 
over glitazones in combination with insulin, especially in view of cost considerations.
Note 5:
Several studies have shown that the addition of a single dose of basal insulin may lead 
to a substantial improvement in FPG and HbAlc. I believe this is the option of choice 
for patients with secondary oral failure on metformin/sulfonylurea who are willing to 
have injections. Most patients with type 2 diabetes will ultimately require insulin due 
to the progressive nature of the disease -  use of a once daily dose of insulin is a safe 
and effective means of improving glycaemic control without being overly daunting to 
the patient.
Note 4:
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I recommend continuation of the oral agents at least initially, in part to ensure that 
glycaemic control doesn’t deteriorate upon initiation of insulin which may be very 
disillusioning for the patient. Both metformin and sulfonylurea have been shown to 
improve glycaemic control when used in combination with insulin (over insulin 
alone). Continued oral agents will also reduce total insulin requirements and lead to 
superior post-prandial glycaemic control -  which may be inadequate on once daily 
basal insulin alone.
What are the benefits of continuation of a sulfonylurea?
There is a large base of evidence supporting both the continuation and the addition of 
sulfonylureas to patients with type 2 diabetes who require insulin. They are generally 
well tolerated, but hypoglycaemic can be problematic. There is insufficient evidence 
to recommend the use of one sulfonylurea over the other. In patients already taking a 
sulfonylurea when they come to need insulin therapy, it is sensible to continue their 
current sulfonylurea in this setting due to its established tolerability. Glibenclamide is 
the most widely studies agent, however some clinicians prefer to use gliclazide due to 
its shorter duration of action.
Addition or continuation of sulfonylurea will improve glycaemic control, with 
additional reductions of HbAlc of over 1% generally being observed where it is 
combined with a simple regimen of once daily basal insulin. In this context it achieves 
fairly comparable glycaemic control to more intensive regimens consisting of multiple 
daily injections of insulin alone. The advantages of commencing with a regimen of 
once daily long-acting insulin + sulfonylurea compared to a multiple daily insulin 
regimen include less weight gain, lower daily insulin requirements, fewer 
hypoglycaemia episodes and greater simplicity for the patient.
Some studies have attempted to classify patients into responders and non-responders -  
it may be useful to assess fasting C-peptide levels in insulin requiring diabetics, to 
help assess if they are likely to benefit from the addition/continuation of a 
sulfonylurea. Patients without evidence of residual endogenous insulin secretion are 
likely to derive less benefit.
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What are the benefits of continuation of metformin?
Metformin achieves similar improvements in HbAlc to the addition of a sulfonylurea. 
Metformin has additional benefits on other metabolic parameters, most notably 
weight gain, but perhaps also blood pressure and lipids. The lack of an association 
with weight gain is an important therapeutic benefit of metformin, especially in type 2 
diabetes where weight reduction is generally recommended. Avoidance of weight 
gain may partially explain the apparent benefits in the risk of macrovascular disease 
observed in obese patients in UKPDS who were assigned to metformin.
In view of these potential benefits I recommend metformin be preferred to 
sulfonylureas in obese type 2 diabetics with secondary oral failure. In non-obese type 
2 diabetics, it may be reasonable to recommend a sulfonylurea in view of their 
superior gastrointestinal tolerability. An alternate approach may be to have a trial of 
metformin first and switch to sulfonylurea only if the metformin is poorly tolerated.
Why should insulin glargine be preferred to NPH insulin?
Insulin glargine is preferable to NPH as its peakless profile more closely mimics 
physiological basal insulin secretion. The absence of a peak reduces the risk of 
nocturnal hypoglycaemia, which can be problematic with bedtime NPH. Insulin 
glargine may also provide superior post-dinner glycaemic control than NPH due to its 
longer duration of action.
However, insulin glargine is yet to convincingly demonstrate superior glycaemic 
control as assessed by HbAlc, compared to NPH. It is possible that in real-world 
clinical practice reduced fear of nocturnal hypoglycaemia with glargine may improve 
adherence to insulin therapy and thus improve glycaemic control (de Sonnaville J et 
al. 1998).
Insulin glargine is significantly more expensive than NPH and is not reimbursed in 
some markets (including Australia as at September 2005). As a result its use may be 
limited to those patients who derive the greatest benefit in particular those who have 
had problems with recurrent nocturnal hypos on NPH.
Due to the progressive nature of type 2 diabetes many patients will ultimately require 
multiple daily injections of insulin. Oral agents become less efficacious in advanced 
E-cell dysfunction. As E-cell secretory function declines, exogenous insulin 
requirements will increase and glycaemic control on once daily insulin (+/- OHAs) 
may become inadequate. In this setting there is good evidence supporting the role of 
multiple daily injections of insulin.
QID regimen vs mixed insulin twice daily?
A QID regimen consisting of bedtime long-acting insulin (NPH or glargine) and 
prandial short-acting insulin comes closest to mimicking normal insulin secretion, but 
there is insufficient data to demonstrate that it is superior to a twice daily regimen 
consisting of a mixture of NPH and short acting insulin. The choice of a QID regimen 
vs a twice daily regimen must therefore be guided by physician and patient 
preference.
Rapid acting insulin analogues vs regular human insulin?
There is some evidence that the newer rapid acting insulin analogues are superior to 
regular human insulin. Their faster onset of action enables greater flexibility in dosing 
time, as they can be administered immediately pre-prandially; this is particularly 
useful to patients with unpredictable meal times or erratic eating habits. Another key 
benefit of the rapid-acting analogues is their superior post-prandial glycaemic control 
compared to regular human insulin. However, this has not been demonstrated to 
achieve superior glycaemic control as assess by HbAlc. A further limitation of the 
newer agents is their higher cost. Overall I feel that there is sufficient evidence to 
recommend the use of the rapid-acting analogues over regular human insulin in 
systems where they are reimbursed.
Any benefit of coutinuatiou of orals?
Once patients have progressed to a QID insulin regimen, there is little benefit to be 
gained from continuation of sulfonylureas due to beta-cell exhaustion. I recommend 
continuation of metformin if tolerated due to benefits as previously outlined. 
Glitazones may also have a role in helping to preserve beta-cell function.
Note 6:
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Patients who wish to avoid a QID insulin regimen should be offered a twice daily 
regimen. Twice daily administration of NPH and short acting insulin has been shown 
to significantly improve glycaemic control in patients with inadequate control on once 
daily insulin (+/- OHAs).
The intermediate and short-acting insulins may be administered separately or as one 
of the commercially available cpre-mixed’ insulin preparations (eg. Mixtard 30/70). 
Separate administration has the advantage of enabling more complex dose 
adjustments and more reliable retention of the different pharmacokinetic profiles of 
the two agents. Advantages of using pre-mixed insulin include simplification for the 
patient and a decrease in the number of injections required. The choice between the 
two should be dictated by physician and patient preference.
Any benefit of continuation of orals?
Once patients have progressed to a twice daily insulin regimen, the issues with respect 
to use of orals are similar to those outlined above for patients on QID insulin. 
Metformin should be continued where tolerated and consideration may be given to the 
use of glitazones (in countries where it is licensed for use in combination with 
insulin).
What is the role of newer premixed formulations of insulin analogues?
Pre-mixed formulations of the newer rapid-acting insulins are now also available (eg. 
Mix25, BIAsp25) with similar advantages to those outlined above in note 6. Their use 
should be guided by physician and patient preference, as well as subsidised 
availability.
Note 7:
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Conclusions
The benefits of tight glycaemic control in type 2 diabetes are now clearly established. 
Patients should be educated as to these benefits and understand the goals of treatment. 
The progressive nature of type 2 diabetes means that most patients will ultimately 
require multiple therapies to achieve acceptable glycaemic control. Insulin has a vital 
role to play in the management of type 2 diabetes and patients should be counselled as 
to the expectation of requiring insulin at some stage during the course of their 
management.
The step-wise treatment algorithm I have proposed takes account of clinical data from 
88 randomised controlled trials undertaken in this arena. Despite this extensive 
evidence base, some treatment decisions must be made in the face of an incomplete 
data. In this setting, it is important to discuss the potential pros and cons of different 
options with the patient, so that they can make an informed choice as to which suits 
their individual needs the best.
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Appendix 1 - M E D L I N E  Search String (executed D e c e m b e r  20th 2003)
# Search History Results
1 *INSULIN/tu [Therapeutic U se] 4000
2 1 and exp clinical trials/ 197
3 1 and clinical trial.pt. 634
4 1 and (clinical adj trial$l).ti,ab. 76
5 or/2-4 746
6 5 and random$.ti,ab. 369
7 1 and randomized controlled trials/ 38
8 1 and randomized controlled trial.pt. 408
9 1 and CONTROLLED CLINICAL TRIAL.pt. 91
10 1 and random allocation/ 66
11 1 and (random adj allocation).ti,ab. 2
12 1 and (randomly adj allocated).ti,ab. 14
13 1 and allocated sam e random$2.ti,ab. 2
14 1 and double-blind-m ethod/ 125
15 1 and single-blind-m ethod/ 4
16 1 and ((single or double) adj (blind$3 or m ask$3)).ti,ab. 129
17 1 and ((treble or triple) adj (blind$3 or m ask$3)).ti,ab. 0
18 1 and cross?over.ti,ab. 71
19 1 and placebos/ 29
20 1 and placebo$l .ti,ab. 117
21 1 and ((random$4 adj controlled) and trial$l).ti,ab. 49
22 1 and rct.ti,ab. 1
23 or/6-22 609
24 (CASE adj REPORT).ti,ab. 96507
25 LETTER.pt. 520048
26 HISTORICAL ARTICLE.pt. 207391
27 REVIEW  OF REPORTED CASES.pt. 48579
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28 REVIEW  M ULTICASE.pt. 7789
29 or/24-28 863648
30 23 not 29 589
31 *Diabetes M ellitus, N on-Insulin-Dependent/ 23310
32 30 and 31 197
33 limit 32 to english language 183
34 limit 33 to abstracts 177
35 limit 34 to yr= 1966-2004 177
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Appendix 2 - E M B A S E  Search String (executed 24th D e c e m b e r  2003)
# Search History Results
1 *INSULIN/dt [D rug T herapy] 7380
2 1 and exp clinical trials/ 888
3 1 and (clinical adj trial$l).ti,ab. 118
4 1 and ct.fs. 620
5 1 and controlled study/ 2114
6 or/2-5 2576
7 6 and random$.ti,ab. 425
8 1 and randomized controlled trial/ 278
9 1 and randomization/ 20
10 1 and single blind procedure/ 10
11 1 and double blind procedure/ 83
12 1 and ((single or double) adj (blind$3 or m ask$3)).ti,ab. 113
13 1 and ((treble or triple) adj (blind$3 or mask$3)).ti,ab. 0
14 1 and crossover procedure/ 75
15 1 and cross?over.ti,ab. 67
16 1 and placebo/ 119
17 1 and p lacebo$l.ti,ab . 157
18 1 and ((random$4 adj controlled) and trial$l).ti,ab. 51
19 1 and rct.ti,ab. 2
20 1 and (random adj allocation).ti,ab. 2
21 1 and (randomly adj allocated).ti,ab. 21
22 1 and allocated sam e random.ti,ab. 0
23 1 and prospective study/ 64
24 or/7-23 705
25 case study/ 3254
26 (case adj report).ti,ab. 80026
27 abstract-report/ 71104
28 letter/ 264607
29 or/25-28 417814
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30 24 not 29 695
31 *Non Insulin Dependent D iabetes M ellitus/dt [Drug Therapy] 5878
32 30 and 31 222
33 lim it 32 to english language 201
34 lim it 33 to abstracts 186
35 lim it 34 to yr= 1980-2004 186
Appendix 3: MEDLINE Eligible Studies after title and abstract review
(n=58)
The MEDLINE search yielded a total of 177 studies. After reviewing all titles and 
abstracts 58 were considered eligible for further evaluation.
1. Authors - HOE 901/2004 Study Investigators Group.
Title - Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in 
combination with oral treatment in Type 2 diabetic patients.
Source - Diabetic Medicine. 20(7):545-51, 2003 Jul.
2. Authors - Wulffele MG. Kooy A. Lehert P. Bets D. Ogterop JC. Borger van der Burg
B. Donker AJ. Stehouwer CD.
Title - Combination of insulin and metformin in the treatment of type 2 diabetes.
Source - Diabetes Care. 25( 12):2133-40, 2002 Dec.
3. Authors - Herz M. Arora V. Campaigne BN. Scholtz HE. Potgieter MA. Mollentze W. 
Title - Humalog Mix25 improves 24-hour plasma glucose profiles compared with the 
human insulin mixture 30/70 in patients with type 2 diabetes mellitus.
Source - South African Medical Journal. 93(3):219-23, 2003 Mar.
4. Authors - Strowig SM. Aviles-Santa ML. Raskin P.
Title - Comparison of insulin monotherapy and combination therapy with insulin and 
metformin or insulin and troglitazone in type 2 diabetes.
Source - Diabetes Care. 25(10): 1691-8, 2002 Oct.
5 . Authors - Herz M. Profozic V. Arora V. Smircic-Duvnjak L. Kovacevic I . Boras J. 
Campaigne BN. Metelko Z.
Title - Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose 
during and after moderate physical exercise in patients with type 2 diabetes.
Source - Current Medical Research & Opinion. 18(4): 188-93, 2002.
6. #Authors- UK Prospective Diabetes Study (UKPDS) Group.
Title - Intensive blood-glucose control with sulphonylureas or insulin compared with 
conventional treatment and risk of complications in patients with type 2 diabetes 
(UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Source - Lancet. 352(9131):837-53, 1998 Sep 12.
7 .  # Authors -  Turner RC. Cull CA. Frighi V. Holman RR.
Title - Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with 
type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 
49). UK Prospective Diabetes Study (UKPDS) Group.
Source - JAMA. 281(21):2005-12, 1999 Jun 2.
# UKPDS 33 and UKPDS 49 utilise the same study participants and will be considered 
as one study for the purpose of any meta-analysis conducted. I have included them both 
as they provide different relevant data.
8. Authors - Schwartz S. Raskin P. Fonseca V. Graveline JF.
Institution - Diabetes and Glandular Diseases Clinic, San Antonio, Tex., USA.
Title - Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. 
Troglitazone and Exogenous Insulin Study Group.
Source - New England Journal of Medicine. 338(13):861-6, 1998 Mar 26.
9. Authors -Raskin P. Rendell M. Riddle MC. Dole JF. Freed MI. Rosenstock J. 
Rosiglitazone Clinical Trials Study Group.
Title - A randomized trial of rosiglitazone therapy in patients with inadequately 
controlled insulin-treated type 2 diabetes.
Source - Diabetes Care. 24(7): 1226-32, 2001 Jul.
1 0 . Authors - Rosenstock J. Schwartz SL. Clark CM Jr. Park GD. Donley DW. Edwards 
MB.
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Title - Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine 
(HOE 901) and NPH insulin.
Source - Diabetes Care. 24(4):631-6, 2001 Apr.
11. Authors - Yki-Jarvinen H. Dressier A. Ziemen M. HOE 901/300s Study Group.
Title - Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime 
insulin glargine compared with bedtime NPH insulin during insulin combination therapy 
in type 2 diabetes. HOE 901/3002 Study Group.
Source - Diabetes Care. 23(8): 1130-6, 2000 Aug.
12. Authors - Boehm BO. Home PD. Behrend C. Kamp NM. Lindholm A.
Institution - Universitatsklinikum Ulm, Ulm, Germany, bernhardm@medizin.uni-ulm.de 
Title - Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a 
randomized trial in Type 1 and Type 2 diabetic patients.
Source - Diabetic Medicine. 19(5):393-9, 2002 May.
13. Authors - Zargar AH. Masoodi SR. La way BA. Wani AI. Bashir MI.
Title - Response of regimens of insulin therapy in type 2 diabetes meliitus subjects with 
secondary failure.
Source - Journal of the Association of Physicians of India. 50(5):641-6, 2002 May.
14. Authors - Rosenstock J. Einhorn D. Hershon K. Glazer NB. Yu S. Pioglitazone 014 
Study Group.
Title - Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, 
placebo-controlled study in patients receiving stable insulin therapy.
Source - International Journal of Clinical Practice. 56(4):251-7, 2002 May.
15. Authors - Herz M. Sun B. Milicevic Z. Erickson P. Fovenyi J. Grzywa M. Pelikanova 
T.
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Title - Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus 
glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.
Source - Clinical Therapeutics. 24(l):73-86, 2002 Jan.
16. Authors - Hermann LS. Kalen J. Katzman P. Lager I. Nilsson A. Norrhamn O. Sartor 
G. Ugander L.
Title - Long-term glycaemic improvement after addition of metformin to insulin in 
insulin-treated obese type 2 diabetes patients.
Source - Diabetes, Obesity & Metabolism. 3(6):428-34, 2001 Dec.
17. Authors - Ross SA. Zinman B. Campos RV. Strack T. Canadian Lispro Study Group. 
Title - A comparative study of insulin lispro and human regular insulin in patients with 
type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
Source - Clinical & Investigative Medicine - Medecine Clinique et Experimentale. 
24(6):292-8, 2001 Dec.
18. Authors - Roach. Koledova E. Metcalfe S. Hultman C. Milicevic Z. Romania/Russia 
Mix25 Study Group.
Title - Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled 
with glyburide.
Source - Clinical Therapeutics. 23(10): 1732-44, 2001 Oct.
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Title - Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. 
Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 
2 Diabetes Feasibility Trial Investigators.
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Title - Diabetic neuropathy in elderly Type 2 diabetic patients: effects of insulin 
treatment.
Source - Acta Neurologica Scandinavica. 98(5):346-53, 1998 Nov.
24. Authors - Emanuele N. Azad N. Abraira C. Henderson W. Colwell J. Levin S. Nuttall 
F. Comstock J. Sawin C. Silbert C. Marcovina S. Lee HS.
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with secondary failure to conventional oral treatment.
Source - Diabetes, Nutrition & Metabolism - Clinical & Experimental. Vol. 9(2)(pp 81- 
88), 1996.
28. Authors - Raucoules-Aime M. Labib Y. Levraut J. Gastaud P. Dolisi C. Grimaud D. 
Title - Use o f i.v. insulin in well-controlled non-insulin-dependent diabetics 
undergoing major surgery.
Source - BJA: British Journal o f Anaesthesia. Vol. 76(2)(pp 198-202), 1996.
29. Authors - Franz MJ. Splett PL. Monk A. Barry B. McClain K. Weaver T. Upham P. 
Bergenstal R. Mazze RS.
Title - Cost-effectiveness o f medical nutrition therapy provided by dietitians for persons 
with non-insulin-dependent diabetes mellitus.
Source - Journal o f the American Dietetic Association. Vol. 95(9)(pp 1018-1024), 1995.
30. Authors - Franz MJ. Monk A. Barry B. McClain K. Weaver T. Cooper N. Upham P. 
Bergenstal R. Mazze RS.
Title - Effectiveness o f  medical nutrition therapy provided by dietitians in the 
management o f non-insulin-dependent diabetes mellitus: A  randomized, controlled 
clinical trial.
Source - Journal o f the American Dietetic Association. Vol. 95(9)(pp 1009-1017), 1995.
31. Authors - Coates PA. Ismail IS. Luzio SD. Griffiths I. Ollerton RL. Volund A. Owens 
DR.
Title - Intranasal insulin: The effects o f three dose regimens on postprandial glycaemic 
profiles in type II diabetic subjects.
Source - Diabetic Medicine. Vol. 12(3)(pp 235-239), 1995.
32. Authors - Morgan WA. Raskin P. Rosenstock J.
Title - A  comparison o f fish oil or corn oil supplements in hyperlipidemic subjects with 
NIDDM.
Source - Diabetes Care. Vol. 18(l)(pp 83-86), 1995.
33. Authors - Brooks B. Cistulli PA. Borkman M. Ross G. McGhee S. Grunstein RR. 
Sullivan CE. Yue DK.
Title - Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: Effect o f 
continuous positive airway pressure treatment on insulin responsiveness.
Source - Journal o f Clinical Endocrinology & Metabolism. Vol. 79(6)(pp 1681-1685), 
1994.
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34. Authors - Willey KA. Molyneaux LM. Yue DK.
Title - Obese patients with Type 2 diabetes poorly controlled by insulin and metformin: 
Effects o f adjunctive dexfenfluramine therapy on glycaemic control.
Source - Diabetic Medicine. Vol. 1 l(7)(pp 701-704), 1994.
35. Authors - _Nielsen S. Schmitz O. Moller N. Porksen N. Klausen IC. Alberti KGMM. 
Mogensen CE.
Title - Renal function and insulin sensitivity during simvastatin treatment in Type 2 (non- 
insulin-dependent) diabetic patients with microalbuminuria.
Source - Diabetologia. Vol. 36(10)(pp 1079-1086), 1993.
36. Authors - Laager R. Keller U.
Title - Effects o f recombinant human insulin-like growth factor I and insulin on 
counterregulation during acute plasma glucose decrements in normal and Type 2 
(non-insulin-dependent) diabetes subjects.
Source - Diabetologia. Vol. 36(10)(pp 966-971), 1993.
37. Authors - Laube BL. Georgopoulos A. Adams III GK.
Title - Preliminary study o f the efficacy o f insulin aerosol delivered by oral inhalation in 
diabetic patients.
Source - Journal o f the American Medical Association. Vol. 269(16)(pp 2106-2109), 
1993.
38. Authors - Coscelli C. Calabrese G. Fedele D. Pisu E. Calderini C. Bistoni S. Lapolla
A. Mauri MG. Rossi A. Zappella A.
Title - Use o f premixed insulin among the elderly: Reduction o f errors in patient 
preparation o f mixtures.
Source - Diabetes Care. Vol. 15(1 l)(pp 1628-1630), 1992.
39. Authors - B ruce D G . C hisho lm  D J. S torlien  L H . B orkm an M . K raegen E W .
Title - Meal-time intranasal insulin delivery in Type 2 diabetes.
Source - Diabetic Medicine. Vol. 8(4)(pp 366-370), 1991.
40. Authors - Quatraro A. Consoli G. Magno M. Caretta F. Nardozza A. Ceriello A. 
Giugliano D.
Title - Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent 
diabetes mellitus. A  new job  for an old drug?.
Source - Annals o f Internal Medicine. Vol. 112(9)(pp 678-681), 1990.
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A U S T R A L IA
E-mail - ldernanhughes@hotmail.com
December 12, 2003 
Eli Lilly & Co Ltd 
Dextra Court, Chapel Hill 
Basingstoke, Hants RG21 5SY
Dear Sir/Madam,
I am writing to request your assistance with a research project. I am a Medical Registrar at 
Prince of Wales Hospital, Sydney. I am currently studying toward a Master of Science in 
Pharmaceutical Medicine at the University of Surrey, UK. As part of the course requirements
1 am undertaking a dissertation consisting of a systematic review of the use of insulin in type
2 diabetes meliitus. My aim is to establish what evidence exists supporting the use of various 
formulations/regimes and what is the best way of combining insulin with oral hypoglycaemic 
agents.
As you are among the market leaders in this therapeutic area, I am writing to seek your 
assistance in identifying trials conducted in this area. I am particularly interested in obtaining 
any trial data that you may have that is unpublished, but would also be thankful for your 
guidance in referring to me to what you may consider the most significant trials.
I am happy to receive correspondence either via post to my home address or electronically at 
lciernanhughes @hotmail .com.
Many thanks for your assistance in this regard.
Sincerely,
D r  K iernan Hughes
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Eli Lilly Australia Pty Ltd (Aust) 
112 Wharf road 
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- Eli Lilly & Co Ltd (UK) 
Dextra Court, Chapel Hill 
Basingstoke, Hants RG21 5SY
- Aventis Pharma Ltd, (UK) Aventis House, 
50 Kings Hill Av, Kings Hill,
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- Aventis Pharma Pty Ltd (Aust) 
27 Sirius Road 
Lane Cove NSW 2066
Novo Nordisk Pharmaceuticals Pty Ltd (Aust)
PO Box 7586
Baulkam Hills NSW 2153
- Novo Nordisk Ltd (UK) 
Broadfield Park, Brighton Rd, 
Crawley, West Sussex RH11 9RT
Appendix 9: 
Final list of eligible studies for inclusion in final review (11=88) 
References for pp92-122
Of the 95 studies considered eligible after title and abstract review, 7 were excluded after 
in depth review of the full publications revealed major quality issues or other factors that 
meant they didn’t meet criteria for inclusion in the final analysis. A total of 88 studies 
were therefore included in the final analysis.
1. Authors - HOE 901/2004 Study Investigators Group.
Title - Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in 
combination with oral treatment in Type 2 diabetic patients.
Source - Diabetic Medicine. 20(7):545-51, 2003 Jul.
2. Authors - Wulffele MG. Kooy A. Lehert P. Bets D. Ogterop JC. Borger van der Burg
B. Donker AJ. Stehouwer CD.
Title - Combination of insulin and metformin in the treatment of type 2 diabetes.
Source - Diabetes Care. 25(12):2133-40, 2002 Dec.
3. Authors - Herz M. Arora V. Campaigne BN. Scholtz HE. Potgieter MA. Mollentze W. 
Title - Humalog Mix25 improves 24-hour plasma glucose profiles compared with the 
human insulin mixture 30/70 in patients with type 2 diabetes mellitus.
Source - South African Medical Journal. 93(3):219-23, 2003 Mar.
4. Authors - Strowig SM. Aviles-Santa ML. Raskin P.
Title - Comparison of insulin monotherapy and combination therapy with insulin and 
metformin or insulin and troglitazone in type 2 diabetes.
Source - Diabetes Care. 25(10): 1691-8, 2002 Oct.
5. Authors - Herz M. Profozic V. Arora V. Smircic-Duvnjak L. Kovacevic I. Boras J. 
Campaigne BN. Metelko Z.
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Title - Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose 
during and after moderate physical exercise in patients with type 2 diabetes.
Source - Current Medical Research & Opinion. 18(4): 188-93, 2002.
6. #Authors- UK Prospective Diabetes Study (UKPDS) Group.
Title - Intensive blood-glucose control with sulphonylureas or insulin compared with 
conventional treatment and risk of complications in patients with type 2 diabetes 
(UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Source - Lancet. 352(9131):837-53, 1998 Sep 12.
7. #Authors - Turner RC. Cull CA. Frighi V. Holman RR.
Title - Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with 
type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 
49). UK Prospective Diabetes Study (UKPDS) Group.
Source - JAMA. 281(21):2005-12, 1999 Jun 2.
# UKPDS 33 and UKPDS 49 utilise the same study participants and will be considered 
as one study for the purpose o f any meta-analysis conducted. 1 have included them both 
as they provide different relevant data.
8. Authors - Schwartz S. Raskin P. Fonseca V. Graveline JF.
Institution - Diabetes and Glandular Diseases Clinic, San Antonio, Tex., USA.
Title - Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. 
Troglitazone and Exogenous Insulin Study Group.
Source - New England Journal of Medicine. 338(13):861-6, 1998 Mar 26.
9. Authors -Raskin P. Rendell M. Riddle MC. Dole JF. Freed MI. Rosenstock J. 
Rosiglitazone Clinical Trials Study Group.
Title - A randomized trial of rosiglitazone therapy in patients with inadequately 
controlled insulin-treated type 2 diabetes.
Source - Diabetes Care. 24(7): 1226-32, 2001 Jul.
10. Authors - Rosenstock J. Schwartz SL. Clark CM Jr. Park GD. Donley DW. Edwards 
MB.
Title - Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine 
(HOE 901) and NPH insulin.
Source - Diabetes Care. 24(4):631-6, 2001 Apr.
11. Authors - Yki-Jarvinen H. Dressier A. Ziemen M. HOE 901/300s Study Group.
Title - Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime 
insulin glargine compared with bedtime NPH insulin during insulin combination therapy 
in type 2 diabetes. HOE 901/3002 Study Group.
Source - Diabetes Care. 23(8): 1130-6, 2000 Aug.
12. Authors - Boehm BO. Home PD. Behrend C. Kamp NM. Lindholm A.
Institution - Universitatsklinikum Ulm, Ulm, Germany, bernhardm@medizin.uni-ulm.de 
Title - Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a 
randomized trial in Type 1 and Type 2 diabetic patients.
Source - Diabetic Medicine. 19(5):393-9, 2002 May.
13. Authors - Zargar AH. Masoodi SR. Laway BA. Wani AI. Bashir MI.
Title - Response of regimens of insulin therapy in type 2 diabetes meliitus subjects with 
secondary failure.
Source - Journal of the Association of Physicians of India. 50(5):641-6, 2002 May.
14. Authors - Rosenstock J. Einhorn D. Hershon K. Glazer NB. Yu S. Pioglitazone 014 
Study Group.
Title - Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, 
placebo-controlled study in patients receiving stable insulin therapy.
Source - International Journal of Clinical Practice. 56(4):251-7, 2002 May.
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15. Authors - Herz M. Sun B. Milicevic Z. Erickson P. Fovenyi J. Grzywa M. Pelikanova 
T.
Title - Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus 
glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.
Source - Clinical Therapeutics. 24(l):73-86, 2002 Jan.
16. Authors - Hermann LS. Kalen J. Katzman P. Lager I. Nilsson A. Norrhamn O. Sartor
G. Ugander L.
Title - Long-term glycaemic improvement after addition of metformin to insulin in 
insulin-treated obese type 2 diabetes patients.
Source - Diabetes, Obesity & Metabolism. 3(6):428-34, 2001 Dec.
17. Authors - Ross SA. Zinman B. Campos RV. Strack T. Canadian Lispro Study Group. 
Title - A comparative study of insulin lispro and human regular insulin in patients with 
type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
Source - Clinical & Investigative Medicine - Medecine Clinique et Experimentale. 
24(6):292-8, 2001 Dec.
18. Authors - Roach. Koledova E. Metcalfe S. Hultman C. Milicevic Z. Romania/Russia 
Mix25 Study Group.
Title - Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled 
with glyburide.
Source - Clinical Therapeutics. 23(10): 1732-44, 2001 Oct.
19. Authors - Ponssen HH. Elte JW. Lehert P. Schouten JP. Bets D.
Title - Combined metformin and insulin therapy for patients with type 2 diabetes 
mellitus.
Source - Clinical Therapeutics. 22(6):709-18, 2000 Jun.
20. Authors - Guvener N. Gedik O.
Title - Effects of combination of insulin and acarbose compared with insulin and
gliclazide in type 2 diabetic patients.
Source - Acta Diabetologica. 36(l-2):93-7, 1999 Jun.
21. Authors - Aviles-Santa L. Sinding J. Raskin P.
Title - Effects of metformin in patients with poorly controlled, insulin-treated type 2 
diabetes meliitus. A randomized, double-blind, placebo-controlled trial.
Source - Annals of Internal Medicine. 131(3): 182-8, 1999 Aug 3.
22. Authors - Standi E. Baumgartl HJ. Fuchtenbusch M. Stemplinger J.
Title - Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late 
failure of sulphonylurea therapy.
Source - Diabetes, Obesity & Metabolism. l(4):215-20, 1999 Jul.
23. Authors - Abraira C. Henderson WG. Colwell JA. Nuttall FQ. Comstock JP. 
Emanuele NV. Levin SR. Sawin CT. Silbert CK.
Title - Response to intensive therapy steps and to glipizide dose in combination with 
insulin in type 2 diabetes. VA feasibility study on glycemic control and complications 
(VA CSDM).
Source - Diabetes Care. 21(4):574-9, 1998 Apr.
24. Authors - Niazi R. Muzaffar Z.
Title - Comparison of bedtime NPH insulin or metformin combined with glibenclamide 
in secondary sulphonylurea failure in obese type II (NIDDM) patients.
Source - JPMA - Journal of the Pakistan Medical Association. 48(11):336-8, 1998 Nov.
25. Authors - Tovi J. Ingemansson SO. Engfeldt P.
Title - Insulin treatment of elderly type 2 diabetic patients: effects on retinopathy.
Source - Diabetes & Metabolism. 24(5):442-7, 1998 Nov.
26 . Authors - R e lim p io  F . P um ar A . Losada F . M angas M A . Acosta D . A storga R .
Title - Adding metformin versus insulin dose increase in insulin-treated but poorly 
controlled Type 2 diabetes mellitus: an open-label randomized trial.
Source - Diabetic Medicine. 15(12):997-1002, 1998 Dec.
27. Authors - Buse JB. Gumbiner B. Mathias NP. Nelson DM. Faja BW. Whitcomb RW. 
Title - Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone 
Insulin Study Group.
Source - Diabetes Care. 21 (9): 1455-61, 1998 Sep.
28. Authors - Penfornis A. Millot L.
Title - Initiating insulin treatment in insulin-requiring type 2 diabetic patients: 
comparative efficiency and cost of outpatient and inpatient management. INNOV Study 
Group.
Source - Diabetes & Metabolism. 24(2): 137-42, 1998 Apr.
29. Authors - Birkeland KI. Rishaug U. Hanssen KF. Vaaler S.
Title - NIDDM: a rapid progressive disease. Results from a long-term, randomised, 
comparative study of insulin or sulphonylurea treatment.
Source - Diabetologia. 39(12): 1629-33, 1996 Dec.
30. Authors - Fanghanel G. Sanchez-Reyes L. Trujillo C. Sotres D. Espinosa-Campos J. 
Title - Metformin's effects on glucose and lipid metabolism in patients with secondary 
failure to sulfonylureas.
Source - Diabetes Care. 19(11): 1185-9, 1996 Nov.
31. Authors - Ravnik-Oblak M. Mrevlje F.
Title - Insulin versus a combination of insulin and sulfonylurea in the treatment of 
NIDDM patients with secondary oral failure.
Source - Diabetes Research & Clinical Practice. 30(l):27-35, 1995 Oct.
32. Authors - Calle-Pascual AL. Garcia-Honduvilla J. Martin-Alvarez PJ. Vara E. Calle 
JR. Munguira ME. Maranes JP.
Title - Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic 
patients with secondary failure to sulfonylurea treatment.
Source - Diabete et Metabolisme. 21(4):256-60, 1995 Oct.
33. Authors - Ohkubo Y. Kishikawa H. Araki E. Miyata T. Isami S. Motoyoshi S. Kojima 
Y. Furuyoshi N. Shichiri M.
Title - Intensive insulin therapy prevents the progression of diabetic microvascular 
complications in Japanese patients with non-insulin-dependent diabetes mellitus: 
a randomized prospective 6-year study.
Source - Diabetes Research & Clinical Practice. 28(2): 103-17, 1995 May.
34. Authors - Landstedt-Hallin L. Adamson U. Arner P. Bolinder J. Lins PE.
Title - Comparison of bedtime NPH or preprandial regular insulin combined with 
glibenclamide in secondary sulfonylurea failure.
Source - Diabetes Care. 18(8): 1183-6, 1995 Aug.
35. Authors - Coniff RF. Shapiro JA. Seaton TB. Hoogwerf BJ. Hunt JA.
Title - A double-blind placebo-controlled trial evaluating the safety and efficacy of 
acarbose for the treatment of patients with insulin-requiring type II diabetes.
Source - Diabetes Care. 18(7):928-32, 1995 Jul.
36. Authors - Chow CC. Tsang LW. Sorensen JP. Cockram CS.
Title - Comparison of insulin with or without continuation of oral hypoglycemic agents in 
the treatment of secondary failure in NIDDM patients.
Source - Diabetes Care. 18(3):307-14, 1995 Mar.
37. Authors - Riddle M. Hart J. Bingham P. Garrison C. McDaniel P.
Title - Combined therapy for obese type 2 diabetes: suppertime mixed insulin with 
daytime sulfonylurea.
Source - American Journal of the Medical Sciences. 303(3): 151 -6, 1992 Mar.
38. Authors - Klein W.
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Title - Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in 
secondary failures of sulfonylurea monotherapy. Results of a prospective randomized 
study in 50 patients.
Source - Diabete et Metabolisme. 17(1 Pt2):235-40, 1991 May.
39. Authors - Groop L. Widen E.
Title - Treatment strategies for secondary sulfonylurea failure. Should we start insulin or 
add metformin? Is there a place for intermittent insulin therapy?.
Source - Diabete et Metabolisme. 17(1 Pt 2):218-23, 1991 May.
4 0 .  Authors - Paterson KR. Wilson M. Kesson CM. Buchan M. Roberts M. Reith SB. 
Davidson E.
Title - Comparison of basal and prandial insulin therapy in patients with secondary 
failure of sulphonylurea therapy.
Source - Diabetic Medicine. 8(l):40-3, 1991 Jan.
4 1 .  Authors - Sotaniemi EA. Vierimaa E. Huupponen R. Karvonen I. Vuoti MJ. Rytomaa 
K.
Title - Insulin and sulphonylurea in the therapy of type 2 diabetes.
Source - Diabetes Research & Clinical Practice. 8(3):243-51, 1990 Mar.
4 2 .  Authors - Groop L. Widen E. Franssila-Kallunki A. Ekstrand A. Saloranta C. Schalin
C. Eriksson J.
Title - Different effects of insulin and oral antidiabetic agents on glucose and energy 
metabolism in type 2 (non-insulin-dependent) diabetes meliitus.
Source - Diabetologia. 32(8):599-605, 1989 Aug.
4 3 .  Authors - Lewitt MS. Yu VK. Rennie GC. Carter JN. Marel GM. Yue DK. Hooper 
MJ.
Title - Effects of combined insulin-sulfonylurea therapy in type II patients.[comment]. 
Source - Diabetes Care. 12(6):379-83, 1989 Jun.
44. Authors - Casner PR.
Title - Insulin-glyburide combination therapy for non-insulin-dependent diabetes 
mellitus: a long-term double-blind, placebo-controlled trial.
Source - Clinical Pharmacology & Therapeutics. 44(5):594-603, 1988 Nov.
45.Authors - Lins PE. Lundblad S. Persson-Trotzig E. Adamson U.
Title - Glibenclamide improves the response to insulin treatment in non-insulin- 
dependent diabetics with second failure to sulfonylurea therapy.
Source - Acta Medica Scandinavica. 223(2): 171-9, 1988.
46. Authors - Holman RR. Steemson J. Turner RC.
Title - Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin 
supplement.
Source - Diabetic Medicine. 4(5):457-62, 1987 Sep-Oct.
4 7 .  Authors - Samanta A. Burden AC. Kinghorn HA.
Title - A comparative study of sulphonylurea and insulin therapy in non insulin 
dependent diabetics who had failed on diet therapy alone.
Source - Diabetes Research. 4(4): 183-5, 1987 Apr.
4 8 .  Authors - Quatraro A. Consoli G. Ceriello A. Giugliano D .
Title - Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics 
with secondary failure to oral drugs: a one year follow-up.
Source - Diabete et Metabolisme. 12(6):315-8, 1986 Dec.
4 9 .  Authors - Mauerhoff T. Ketelslegers JM. Lambert AE.
Title - Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin 
secretion.
Source - Diabete et Metabolisme. 12(1 ):34-8, 1986 Feb.
50. Authors - Falko JM. Osei K.
Title - Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on 
lipoprotein metabolism and glucoregulation.
Source - American Journal of Medicine. 79(3B):92-101, 1985 Sep 20.
51. Authors - Groop L. Harno K. Nikkila EA. Pelkonen R. Tolppanen EM.
Title - Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on 
glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone. 
Source - Acta Medica Scandinavica. 217(l):33-9, 1985.
52. Authors - Groop L. Harno K. Tolppanen EM.
Title - The combination of insulin and sulphonylurea in the treatment of secondary drug 
failure in patients with type II diabetes.
Source - Acta Endocrinologica. 106(1 ):97-l01, 1984 May.
53. Authors - Sargin H. Sargin M. Altuntas Y. Sengul AM. Orbay E. Seber S. Ucak S. 
Yayla A.
Title - Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro 
therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes. 
Source - Diabetes Research & Clinical Practice. Vol. 62(2)(pp 79-86), 2003.
54. Authors - Raskin P. Bode BW. Marks JB. Hirsch IB. Weinstein RL. McGill JB.
Peterson GE. Mudaliar SR. Reinhardt RR.
Title - Continuous subcutaneous insulin infusion and multiple daily injection therapy are 
equally effective in type 2 diabetes: A randomized, parallel-group, 24-week study.
Source - Diabetes Care. Vol. 26(9)(pp 2598-2603), 2003.
55. Authors - Schwartz S. Sievers R. Strange P. Lyness WH. Hollander P.
Title - Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of 
type 2 diabetes after failure of two oral drugs: Efficacy, safety, and cost analysis.
Source - Diabetes Care. Vol. 26(8)(pp 2238-2243), 2003.
5 6 .  Authors - Alvarsson M. Sundkvist G. Lager I. Henricsson M. Berntorp K. Fernqvist 
Forbes E. Steen L. Westermark G. Westermark P. Orn T. Grill V.
Title - Beneficial effects of insulin versus sulphonylurea on insulin secretion and 
metabolic control in recently diagnosed type 2 diabetic patients.
Source - Diabetes Care. Vol. 26(8)(pp 2231-2237), 2003.
5 7 .  Authors - Hwu C-M. Ho L-T. Fuh MMT. Siu SC. Sutanegara D. Piliang S. Chan 
JCN.
Title - Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic 
patients: Results from a multinational, placebo-controlled study.
Source - Diabetes Research & Clinical Practice. Vol. 60(2)(pp 111-118), 2003.
5 8 .  Authors - Stehouwer MHA. DeVries JH. Lumeij JAE. Ader HJ. Engbers AMS. van 
Iperen A. Snoek FJ. Heine RJ.
Title - Combined bedtime insulin - Daytime sulphonylurea regimen compared with two 
different daily insulin regimens in type 2 diabetes: Effects on HbAlc and hypoglycaemia 
rate - A randomised trial.
Source - Diabetes/Metabolism Research Reviews. Vol. 19(2)(pp 148-152), 2003.
5 9 .  Authors - Kelley DE. Bidot P. Freedman Z. Haag B. Podlecki D. Rendell M. Schimel
D. Weiss S. Taylor T. Krol A. Magner J.
Title - Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. 
Source - Diabetes Care. Vol. 21(12)(pp 2056-2061), 1998.
6 0 .  Authors - Robinson AC. Burke J. Robinson S. Johnston DG. Elkeles RS.
Title - The effects of metformin on glycemic control and serum lipids in insulin-treated 
NIDDM patients with suboptimal metabolic control.
Source - Diabetes Care. Vol. 21(5)(pp 701-705), 1998.
61. Authors - Riddle MC. Schneider J.
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Title - Beginning insulin treatment of obese patients with evening 70/30 insulin plus 
glimepiride versus insulin alone.
Source - Diabetes Care. Vol. 21(7)(pp 1052-1057), 1998.
6 2 .  Authors - Feinglos MN. Thacker CR. Lobaugh B. DeAtkine DD. McNeill DB. 
English JS. Bursey DL.
Title - Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes 
mellitus.
Source - Diabetes Research & Clinical Practice. Vol. 39(3)(pp 193-199), 1998.
63. Authors - Anderson JH Jr. et al
Title - Improved mealtime treatment of diabetes mellitus using an insulin analogue. 
Source - Clinical Therapeutics. Vol. 19(l)(pp 62-72), 1997.
6 4 .  Authors - Saudek CD. Et al
Title - Implantable insulin pump vs multiple-dose insulin for non-insulin- dependent 
diabetes mellitus: A randomized clinical trial.
Source - Journal of the American Medical Association. Vol. 276(16)(pp 1322-1327), 
1996.
65. Authors - Clauson P. Karlander S. Steen L. Efendic S.
Title - Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin 
treatment in secondary sulphonylurea failure: A 1-year follow-up.
Source - Diabetic Medicine. Vol. 13(5)(pp 471-477), 1996.
66. Authors - Taylor R. Foster B. Kyne-Grzebalski D. Vanderpump M.
Title - Insulin regimens for the non-insulin dependent: Impact on diurnal metabolic state 
and quality of life.
Source - Diabetic Medicine. Vol. 1 l(6)(pp 551-557), 1994.
6 7 .  Authors - Giugliano D. Quatraro A. Consoli G. Minei A. Ceriello A. De Rosa N. 
D'Onofrio F.
Title - Metformin for obese, insulin-treated diabetic patients: Improvement in glycaemic 
control and reduction of metabolic risk factors.
Source - European Journal of Clinical Pharmacology. Vol. 44(2)(pp 107-112), 1993.
68. Authors - Riddle MC. Hart JS. Bouma DJ. Phillipson BE. Youker G.
Title - Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of 
type II diabetic subjects.
Source - Diabetes Care. Vol. 12(9)(pp 623-629), 1989.
69. Authors - Tindall H. Bodansky HJ. Stickland M. Wales JK.
Title - A strategy for selection of elderly Type 2 diabetic patients for insulin therapy, and 
a comparison of two insulin preparations.
Source - Diabetic Medicine. Vol. 5(6)(pp 533-536), 1988.
7 0 .  Authors -  Fritsche A. Schweitzer MA. Haring HU. 4001 Study Group.
Title - Glimepiride combined with morning insulin glargine, bedtime neutral protamine 
hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A 
randomized, controlled trial.
Source - Annals of Internal Medicine. 138(12):952-9, 2003 Jun 17.
7 1 .  Authors Roach P. Strack T. Arora V. Zhao Z.
Title - Improved glycaemic control with the use of self-prepared mixtures of insulin 
lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. 
Source - International Journal of Clinical Practice. 55(3): 177-82, 2001 Apr.
7 2 .  Authors -  Taylor R. Davies R. Fox C. Sampson M. Weaver JU. Wood L.
Title - Appropriate insulin regimes for type 2 diabetes: a multicenter randomized 
crossover study.
Source -  D iabetes Care. 2 3 (1 1 ): 1612-8 , 2 0 0 0  N o v .
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